id	sid	tid	token	lemma	pos
ajst-26912	1	1	academic	academic	ADJ
ajst-26912	1	2	journal	journal	NOUN
ajst-26912	1	3	of	of	ADP
ajst-26912	1	4	science	science	NOUN
ajst-26912	1	5	and	and	CCONJ
ajst-26912	1	6	technology	technology	NOUN
ajst-26912	1	7	issn	issn	NOUN
ajst-26912	1	8	:	:	PUNCT
ajst-26912	1	9	2771	2771	NUM
ajst-26912	1	10	-	-	SYM
ajst-26912	1	11	3032	3032	NUM
ajst-26912	1	12	|	|	NOUN
ajst-26912	1	13	vol	vol	NOUN
ajst-26912	1	14	.	.	PROPN
ajst-26912	1	15	13	13	NUM
ajst-26912	1	16	,	,	PUNCT
ajst-26912	1	17	no	no	INTJ
ajst-26912	1	18	.	.	NOUN
ajst-26912	1	19	1	1	NUM
ajst-26912	1	20	,	,	PUNCT
ajst-26912	1	21	2024	2024	NUM
ajst-26912	1	22	203	203	NUM
ajst-26912	1	23	clinical	clinical	ADJ
ajst-26912	1	24	application	application	NOUN
ajst-26912	1	25	and	and	CCONJ
ajst-26912	1	26	risk	risk	NOUN
ajst-26912	1	27	assessment	assessment	NOUN
ajst-26912	1	28	of	of	ADP
ajst-26912	1	29	car‐t	car‐t	PROPN
ajst-26912	1	30	cell	cell	NOUN
ajst-26912	1	31	technology	technology	NOUN
ajst-26912	1	32	in	in	ADP
ajst-26912	1	33	cancer	cancer	NOUN
ajst-26912	1	34	immunotherapy	immunotherapy	NOUN
ajst-26912	1	35	liangqi	liangqi	PROPN
ajst-26912	1	36	li	li	PROPN
ajst-26912	1	37	affiliated	affiliate	VERB
ajst-26912	1	38	middle	middle	ADJ
ajst-26912	1	39	school	school	NOUN
ajst-26912	1	40	of	of	ADP
ajst-26912	1	41	henan	henan	PROPN
ajst-26912	1	42	normal	normal	ADJ
ajst-26912	1	43	university	university	NOUN
ajst-26912	1	44	,	,	PUNCT
ajst-26912	1	45	no	no	NOUN
ajst-26912	1	46	.	.	NOUN
ajst-26912	1	47	85	85	NUM
ajst-26912	1	48	jianshe	jianshe	PROPN
ajst-26912	1	49	east	east	PROPN
ajst-26912	1	50	road	road	PROPN
ajst-26912	1	51	,	,	PUNCT
ajst-26912	1	52	muye	muye	PROPN
ajst-26912	1	53	district	district	PROPN
ajst-26912	1	54	,	,	PUNCT
ajst-26912	1	55	xinxiang	xinxiang	PROPN
ajst-26912	1	56	city	city	PROPN
ajst-26912	1	57	,	,	PUNCT
ajst-26912	1	58	henan	henan	PROPN
ajst-26912	1	59	province	province	PROPN
ajst-26912	1	60	,	,	PUNCT
ajst-26912	1	61	china	china	PROPN
ajst-26912	1	62	abstract	abstract	PROPN
ajst-26912	1	63	:	:	PUNCT
ajst-26912	1	64	as	as	ADP
ajst-26912	1	65	a	a	DET
ajst-26912	1	66	cutting	cutting	NOUN
ajst-26912	1	67	-	-	PUNCT
ajst-26912	1	68	edge	edge	NOUN
ajst-26912	1	69	personalized	personalize	VERB
ajst-26912	1	70	treatment	treatment	NOUN
ajst-26912	1	71	method	method	NOUN
ajst-26912	1	72	,	,	PUNCT
ajst-26912	1	73	car	car	NOUN
ajst-26912	1	74	-	-	PUNCT
ajst-26912	1	75	t	t	NOUN
ajst-26912	1	76	cell	cell	NOUN
ajst-26912	1	77	technology	technology	NOUN
ajst-26912	1	78	transforms	transform	VERB
ajst-26912	1	79	patients	patient	NOUN
ajst-26912	1	80	'	'	PART
ajst-26912	1	81	own	own	ADJ
ajst-26912	1	82	t	t	NOUN
ajst-26912	1	83	cells	cell	NOUN
ajst-26912	1	84	through	through	ADP
ajst-26912	1	85	genetic	genetic	ADJ
ajst-26912	1	86	engineering	engineering	NOUN
ajst-26912	1	87	,	,	PUNCT
ajst-26912	1	88	making	make	VERB
ajst-26912	1	89	them	they	PRON
ajst-26912	1	90	have	have	VERB
ajst-26912	1	91	the	the	DET
ajst-26912	1	92	ability	ability	NOUN
ajst-26912	1	93	to	to	PART
ajst-26912	1	94	specifically	specifically	ADV
ajst-26912	1	95	identify	identify	VERB
ajst-26912	1	96	and	and	CCONJ
ajst-26912	1	97	kill	kill	VERB
ajst-26912	1	98	tumor	tumor	NOUN
ajst-26912	1	99	cells	cell	NOUN
ajst-26912	1	100	.	.	PUNCT
ajst-26912	2	1	the	the	DET
ajst-26912	2	2	aim	aim	NOUN
ajst-26912	2	3	of	of	ADP
ajst-26912	2	4	this	this	DET
ajst-26912	2	5	paper	paper	NOUN
ajst-26912	2	6	is	be	AUX
ajst-26912	2	7	to	to	PART
ajst-26912	2	8	thoroughly	thoroughly	ADV
ajst-26912	2	9	organize	organize	VERB
ajst-26912	2	10	the	the	DET
ajst-26912	2	11	foundational	foundational	ADJ
ajst-26912	2	12	principles	principle	NOUN
ajst-26912	2	13	and	and	CCONJ
ajst-26912	2	14	clinical	clinical	ADJ
ajst-26912	2	15	utility	utility	NOUN
ajst-26912	2	16	of	of	ADP
ajst-26912	2	17	car	car	NOUN
ajst-26912	2	18	-	-	PUNCT
ajst-26912	2	19	t	t	NOUN
ajst-26912	2	20	cell	cell	NOUN
ajst-26912	2	21	technology	technology	NOUN
ajst-26912	2	22	,	,	PUNCT
ajst-26912	2	23	highlighting	highlight	VERB
ajst-26912	2	24	its	its	PRON
ajst-26912	2	25	recent	recent	ADJ
ajst-26912	2	26	advancements	advancement	NOUN
ajst-26912	2	27	in	in	ADP
ajst-26912	2	28	treating	treat	VERB
ajst-26912	2	29	both	both	CCONJ
ajst-26912	2	30	hematological	hematological	ADJ
ajst-26912	2	31	and	and	CCONJ
ajst-26912	2	32	solid	solid	ADJ
ajst-26912	2	33	tumors	tumor	NOUN
ajst-26912	2	34	.	.	PUNCT
ajst-26912	3	1	through	through	ADP
ajst-26912	3	2	a	a	DET
ajst-26912	3	3	comprehensive	comprehensive	ADJ
ajst-26912	3	4	assessment	assessment	NOUN
ajst-26912	3	5	of	of	ADP
ajst-26912	3	6	car	car	NOUN
ajst-26912	3	7	-	-	PUNCT
ajst-26912	3	8	t	t	NOUN
ajst-26912	3	9	cell	cell	NOUN
ajst-26912	3	10	technology	technology	NOUN
ajst-26912	3	11	's	's	PART
ajst-26912	3	12	efficacy	efficacy	NOUN
ajst-26912	3	13	and	and	CCONJ
ajst-26912	3	14	risks	risk	NOUN
ajst-26912	3	15	,	,	PUNCT
ajst-26912	3	16	this	this	DET
ajst-26912	3	17	study	study	NOUN
ajst-26912	3	18	aims	aim	VERB
ajst-26912	3	19	to	to	PART
ajst-26912	3	20	inform	inform	VERB
ajst-26912	3	21	clinical	clinical	ADJ
ajst-26912	3	22	decision	decision	NOUN
ajst-26912	3	23	-	-	PUNCT
ajst-26912	3	24	making	making	NOUN
ajst-26912	3	25	.	.	PUNCT
ajst-26912	4	1	initially	initially	ADV
ajst-26912	4	2	,	,	PUNCT
ajst-26912	4	3	the	the	DET
ajst-26912	4	4	paper	paper	NOUN
ajst-26912	4	5	outlines	outline	VERB
ajst-26912	4	6	the	the	DET
ajst-26912	4	7	basic	basic	ADJ
ajst-26912	4	8	mechanisms	mechanism	NOUN
ajst-26912	4	9	of	of	ADP
ajst-26912	4	10	cart	cart	NOUN
ajst-26912	4	11	cell	cell	NOUN
ajst-26912	4	12	technology	technology	NOUN
ajst-26912	4	13	,	,	PUNCT
ajst-26912	4	14	followed	follow	VERB
ajst-26912	4	15	by	by	ADP
ajst-26912	4	16	an	an	DET
ajst-26912	4	17	analysis	analysis	NOUN
ajst-26912	4	18	of	of	ADP
ajst-26912	4	19	its	its	PRON
ajst-26912	4	20	notable	notable	ADJ
ajst-26912	4	21	therapeutic	therapeutic	ADJ
ajst-26912	4	22	outcomes	outcome	NOUN
ajst-26912	4	23	in	in	ADP
ajst-26912	4	24	hematological	hematological	ADJ
ajst-26912	4	25	tumors	tumor	NOUN
ajst-26912	4	26	.	.	PUNCT
ajst-26912	5	1	additionally	additionally	ADV
ajst-26912	5	2	,	,	PUNCT
ajst-26912	5	3	it	it	PRON
ajst-26912	5	4	addresses	address	VERB
ajst-26912	5	5	the	the	DET
ajst-26912	5	6	challenges	challenge	NOUN
ajst-26912	5	7	posed	pose	VERB
ajst-26912	5	8	by	by	ADP
ajst-26912	5	9	solid	solid	ADJ
ajst-26912	5	10	tumor	tumor	NOUN
ajst-26912	5	11	treatment	treatment	NOUN
ajst-26912	5	12	,	,	PUNCT
ajst-26912	5	13	including	include	VERB
ajst-26912	5	14	antigen	antigen	ADJ
ajst-26912	5	15	expression	expression	NOUN
ajst-26912	5	16	complexity	complexity	NOUN
ajst-26912	5	17	and	and	CCONJ
ajst-26912	5	18	tumor	tumor	NOUN
ajst-26912	5	19	microenvironment	microenvironment	ADJ
ajst-26912	5	20	impact	impact	NOUN
ajst-26912	5	21	.	.	PUNCT
ajst-26912	6	1	emphasis	emphasis	NOUN
ajst-26912	6	2	is	be	AUX
ajst-26912	6	3	placed	place	VERB
ajst-26912	6	4	on	on	ADP
ajst-26912	6	5	the	the	DET
ajst-26912	6	6	crucial	crucial	ADJ
ajst-26912	6	7	role	role	NOUN
ajst-26912	6	8	of	of	ADP
ajst-26912	6	9	regulatory	regulatory	ADJ
ajst-26912	6	10	bodies	body	NOUN
ajst-26912	6	11	in	in	ADP
ajst-26912	6	12	enhancing	enhance	VERB
ajst-26912	6	13	oversight	oversight	NOUN
ajst-26912	6	14	and	and	CCONJ
ajst-26912	6	15	developing	develop	VERB
ajst-26912	6	16	risk	risk	NOUN
ajst-26912	6	17	management	management	NOUN
ajst-26912	6	18	strategies	strategy	NOUN
ajst-26912	6	19	to	to	PART
ajst-26912	6	20	safeguard	safeguard	VERB
ajst-26912	6	21	patient	patient	ADJ
ajst-26912	6	22	safety	safety	NOUN
ajst-26912	6	23	.	.	PUNCT
ajst-26912	7	1	keywords	keyword	NOUN
ajst-26912	7	2	:	:	PUNCT
ajst-26912	7	3	tumor	tumor	NOUN
ajst-26912	7	4	immunotherapy	immunotherapy	NOUN
ajst-26912	7	5	;	;	PUNCT
ajst-26912	7	6	car	car	NOUN
ajst-26912	7	7	-	-	PUNCT
ajst-26912	7	8	t	t	NOUN
ajst-26912	7	9	cell	cell	NOUN
ajst-26912	7	10	technology	technology	NOUN
ajst-26912	7	11	;	;	PUNCT
ajst-26912	7	12	clinical	clinical	ADJ
ajst-26912	7	13	application	application	NOUN
ajst-26912	7	14	;	;	PUNCT
ajst-26912	7	15	risk	risk	NOUN
ajst-26912	7	16	management	management	NOUN
ajst-26912	7	17	.	.	PUNCT
ajst-26912	8	1	1	1	X
ajst-26912	8	2	.	.	X
ajst-26912	8	3	introduction	introduction	NOUN
ajst-26912	8	4	human	human	ADJ
ajst-26912	8	5	understanding	understanding	NOUN
ajst-26912	8	6	of	of	ADP
ajst-26912	8	7	tumor	tumor	NOUN
ajst-26912	8	8	has	have	AUX
ajst-26912	8	9	expanded	expand	VERB
ajst-26912	8	10	from	from	ADP
ajst-26912	8	11	a	a	DET
ajst-26912	8	12	single	single	ADJ
ajst-26912	8	13	abnormal	abnormal	ADJ
ajst-26912	8	14	cell	cell	NOUN
ajst-26912	8	15	proliferation	proliferation	NOUN
ajst-26912	8	16	to	to	ADP
ajst-26912	8	17	complex	complex	ADJ
ajst-26912	8	18	genetic	genetic	ADJ
ajst-26912	8	19	variation	variation	NOUN
ajst-26912	8	20	,	,	PUNCT
ajst-26912	8	21	immune	immune	ADJ
ajst-26912	8	22	escape	escape	NOUN
ajst-26912	8	23	and	and	CCONJ
ajst-26912	8	24	other	other	ADJ
ajst-26912	8	25	dimensions	dimension	NOUN
ajst-26912	8	26	[	[	X
ajst-26912	8	27	1	1	NUM
ajst-26912	8	28	]	]	PUNCT
ajst-26912	8	29	.	.	PUNCT
ajst-26912	9	1	in	in	ADP
ajst-26912	9	2	this	this	DET
ajst-26912	9	3	context	context	NOUN
ajst-26912	9	4	,	,	PUNCT
ajst-26912	9	5	tumor	tumor	NOUN
ajst-26912	9	6	immunotherapy	immunotherapy	NOUN
ajst-26912	9	7	breaks	break	VERB
ajst-26912	9	8	the	the	DET
ajst-26912	9	9	limitations	limitation	NOUN
ajst-26912	9	10	of	of	ADP
ajst-26912	9	11	traditional	traditional	ADJ
ajst-26912	9	12	treatment	treatment	NOUN
ajst-26912	9	13	methods	method	NOUN
ajst-26912	9	14	such	such	ADJ
ajst-26912	9	15	as	as	ADP
ajst-26912	9	16	surgery	surgery	NOUN
ajst-26912	9	17	,	,	PUNCT
ajst-26912	9	18	radiotherapy	radiotherapy	NOUN
ajst-26912	9	19	and	and	CCONJ
ajst-26912	9	20	chemotherapy	chemotherapy	NOUN
ajst-26912	9	21	,	,	PUNCT
ajst-26912	9	22	and	and	CCONJ
ajst-26912	9	23	achieves	achieve	VERB
ajst-26912	9	24	a	a	DET
ajst-26912	9	25	precise	precise	ADJ
ajst-26912	9	26	attack	attack	NOUN
ajst-26912	9	27	on	on	ADP
ajst-26912	9	28	tumor	tumor	NOUN
ajst-26912	9	29	cells	cell	NOUN
ajst-26912	9	30	by	by	ADP
ajst-26912	9	31	activating	activate	VERB
ajst-26912	9	32	or	or	CCONJ
ajst-26912	9	33	enhancing	enhance	VERB
ajst-26912	9	34	the	the	DET
ajst-26912	9	35	body	body	NOUN
ajst-26912	9	36	's	's	PART
ajst-26912	9	37	own	own	ADJ
ajst-26912	9	38	immune	immune	ADJ
ajst-26912	9	39	system	system	NOUN
ajst-26912	9	40	,	,	PUNCT
ajst-26912	9	41	bringing	bring	VERB
ajst-26912	9	42	new	new	ADJ
ajst-26912	9	43	hope	hope	NOUN
ajst-26912	9	44	to	to	PART
ajst-26912	9	45	tumor	tumor	NOUN
ajst-26912	9	46	patients	patient	NOUN
ajst-26912	9	47	[	[	X
ajst-26912	9	48	2	2	NUM
ajst-26912	9	49	]	]	PUNCT
ajst-26912	9	50	.	.	PUNCT
ajst-26912	10	1	the	the	DET
ajst-26912	10	2	essence	essence	NOUN
ajst-26912	10	3	of	of	ADP
ajst-26912	10	4	tumor	tumor	NOUN
ajst-26912	10	5	immunotherapy	immunotherapy	NOUN
ajst-26912	10	6	revolves	revolve	VERB
ajst-26912	10	7	around	around	ADP
ajst-26912	10	8	harnessing	harness	VERB
ajst-26912	10	9	the	the	DET
ajst-26912	10	10	body	body	NOUN
ajst-26912	10	11	's	's	PART
ajst-26912	10	12	immune	immune	ADJ
ajst-26912	10	13	system	system	NOUN
ajst-26912	10	14	to	to	PART
ajst-26912	10	15	detect	detect	VERB
ajst-26912	10	16	and	and	CCONJ
ajst-26912	10	17	eradicate	eradicate	VERB
ajst-26912	10	18	cancer	cancer	NOUN
ajst-26912	10	19	cells	cell	NOUN
ajst-26912	10	20	.	.	PUNCT
ajst-26912	11	1	car	car	NOUN
ajst-26912	11	2	-	-	PUNCT
ajst-26912	11	3	t	t	PROPN
ajst-26912	11	4	cell	cell	NOUN
ajst-26912	11	5	technology	technology	NOUN
ajst-26912	11	6	,	,	PUNCT
ajst-26912	11	7	a	a	DET
ajst-26912	11	8	prominent	prominent	ADJ
ajst-26912	11	9	immunotherapy	immunotherapy	NOUN
ajst-26912	11	10	advancement	advancement	NOUN
ajst-26912	11	11	,	,	PUNCT
ajst-26912	11	12	has	have	AUX
ajst-26912	11	13	revolutionized	revolutionize	VERB
ajst-26912	11	14	tumor	tumor	NOUN
ajst-26912	11	15	treatment	treatment	NOUN
ajst-26912	11	16	through	through	ADP
ajst-26912	11	17	its	its	PRON
ajst-26912	11	18	unique	unique	ADJ
ajst-26912	11	19	mechanism	mechanism	NOUN
ajst-26912	11	20	and	and	CCONJ
ajst-26912	11	21	outstanding	outstanding	ADJ
ajst-26912	11	22	results	result	NOUN
ajst-26912	11	23	[	[	X
ajst-26912	11	24	3	3	NUM
ajst-26912	11	25	]	]	PUNCT
ajst-26912	11	26	.	.	PUNCT
ajst-26912	12	1	car	car	NOUN
ajst-26912	12	2	-	-	PUNCT
ajst-26912	12	3	t	t	PROPN
ajst-26912	12	4	,	,	PUNCT
ajst-26912	12	5	short	short	ADJ
ajst-26912	12	6	for	for	ADP
ajst-26912	12	7	chimeric	chimeric	ADJ
ajst-26912	12	8	antigen	antigen	ADJ
ajst-26912	12	9	receptor	receptor	NOUN
ajst-26912	12	10	t	t	NOUN
ajst-26912	12	11	cell	cell	NOUN
ajst-26912	12	12	,	,	PUNCT
ajst-26912	12	13	represents	represent	VERB
ajst-26912	12	14	genetically	genetically	ADV
ajst-26912	12	15	modified	modify	VERB
ajst-26912	12	16	t	t	NOUN
ajst-26912	12	17	lymphocytes	lymphocyte	VERB
ajst-26912	12	18	capable	capable	ADJ
ajst-26912	12	19	of	of	ADP
ajst-26912	12	20	precisely	precisely	ADV
ajst-26912	12	21	recognizing	recognize	VERB
ajst-26912	12	22	and	and	CCONJ
ajst-26912	12	23	attaching	attach	VERB
ajst-26912	12	24	to	to	ADP
ajst-26912	12	25	tumor	tumor	NOUN
ajst-26912	12	26	cell	cell	NOUN
ajst-26912	12	27	surface	surface	NOUN
ajst-26912	12	28	antigens	antigen	NOUN
ajst-26912	12	29	,	,	PUNCT
ajst-26912	12	30	thereby	thereby	ADV
ajst-26912	12	31	triggering	trigger	VERB
ajst-26912	12	32	tcell	tcell	NOUN
ajst-26912	12	33	killing	killing	NOUN
ajst-26912	12	34	activity	activity	NOUN
ajst-26912	12	35	[	[	X
ajst-26912	12	36	4	4	NUM
ajst-26912	12	37	]	]	PUNCT
ajst-26912	12	38	.	.	PUNCT
ajst-26912	13	1	this	this	DET
ajst-26912	13	2	breakthrough	breakthrough	NOUN
ajst-26912	13	3	offers	offer	VERB
ajst-26912	13	4	a	a	DET
ajst-26912	13	5	fresh	fresh	ADJ
ajst-26912	13	6	therapeutic	therapeutic	ADJ
ajst-26912	13	7	avenue	avenue	NOUN
ajst-26912	13	8	for	for	ADP
ajst-26912	13	9	patients	patient	NOUN
ajst-26912	13	10	unresponsive	unresponsive	ADJ
ajst-26912	13	11	to	to	ADP
ajst-26912	13	12	conventional	conventional	ADJ
ajst-26912	13	13	treatments	treatment	NOUN
ajst-26912	13	14	or	or	CCONJ
ajst-26912	13	15	experiencing	experience	VERB
ajst-26912	13	16	relapse	relapse	NOUN
ajst-26912	13	17	.	.	PUNCT
ajst-26912	14	1	building	build	VERB
ajst-26912	14	2	on	on	ADP
ajst-26912	14	3	early	early	ADJ
ajst-26912	14	4	adoptive	adoptive	ADJ
ajst-26912	14	5	cell	cell	NOUN
ajst-26912	14	6	therapy	therapy	NOUN
ajst-26912	14	7	(	(	PUNCT
ajst-26912	14	8	act	act	PROPN
ajst-26912	14	9	)	)	PUNCT
ajst-26912	14	10	,	,	PUNCT
ajst-26912	14	11	car	car	NOUN
ajst-26912	14	12	-	-	PUNCT
ajst-26912	14	13	t	t	NOUN
ajst-26912	14	14	technology	technology	NOUN
ajst-26912	14	15	has	have	AUX
ajst-26912	14	16	benefited	benefit	VERB
ajst-26912	14	17	from	from	ADP
ajst-26912	14	18	gene	gene	NOUN
ajst-26912	14	19	editing	edit	VERB
ajst-26912	14	20	advancements	advancement	NOUN
ajst-26912	14	21	,	,	PUNCT
ajst-26912	14	22	enabling	enable	VERB
ajst-26912	14	23	more	more	ADV
ajst-26912	14	24	precise	precise	ADJ
ajst-26912	14	25	car	car	NOUN
ajst-26912	14	26	-	-	PUNCT
ajst-26912	14	27	t	t	NOUN
ajst-26912	14	28	cell	cell	NOUN
ajst-26912	14	29	design	design	NOUN
ajst-26912	14	30	and	and	CCONJ
ajst-26912	14	31	enhanced	enhance	VERB
ajst-26912	14	32	efficacy	efficacy	NOUN
ajst-26912	14	33	[	[	X
ajst-26912	14	34	5	5	NUM
ajst-26912	14	35	]	]	PUNCT
ajst-26912	14	36	.	.	PUNCT
ajst-26912	15	1	notably	notably	ADV
ajst-26912	15	2	,	,	PUNCT
ajst-26912	15	3	car	car	NOUN
ajst-26912	15	4	-	-	PUNCT
ajst-26912	15	5	t	t	NOUN
ajst-26912	15	6	targeting	target	VERB
ajst-26912	15	7	specific	specific	ADJ
ajst-26912	15	8	tumor	tumor	NOUN
ajst-26912	15	9	antigens	antigen	NOUN
ajst-26912	15	10	like	like	ADP
ajst-26912	15	11	cd19	cd19	PROPN
ajst-26912	15	12	has	have	AUX
ajst-26912	15	13	shown	show	VERB
ajst-26912	15	14	impressive	impressive	ADJ
ajst-26912	15	15	outcomes	outcome	NOUN
ajst-26912	15	16	in	in	ADP
ajst-26912	15	17	treating	treat	VERB
ajst-26912	15	18	relapsed	relapse	VERB
ajst-26912	15	19	or	or	CCONJ
ajst-26912	15	20	refractory	refractory	NOUN
ajst-26912	15	21	b	b	NOUN
ajst-26912	15	22	-	-	PUNCT
ajst-26912	15	23	cell	cell	NOUN
ajst-26912	15	24	lymphoma	lymphoma	NOUN
ajst-26912	15	25	.	.	PUNCT
ajst-26912	16	1	as	as	SCONJ
ajst-26912	16	2	clinical	clinical	ADJ
ajst-26912	16	3	applications	application	NOUN
ajst-26912	16	4	expand	expand	VERB
ajst-26912	16	5	,	,	PUNCT
ajst-26912	16	6	various	various	ADJ
ajst-26912	16	7	risks	risk	NOUN
ajst-26912	16	8	and	and	CCONJ
ajst-26912	16	9	challenges	challenge	NOUN
ajst-26912	16	10	have	have	AUX
ajst-26912	16	11	emerged	emerge	VERB
ajst-26912	16	12	.	.	PUNCT
ajst-26912	17	1	safety	safety	NOUN
ajst-26912	17	2	concerns	concern	NOUN
ajst-26912	17	3	such	such	ADJ
ajst-26912	17	4	as	as	ADP
ajst-26912	17	5	cytokine	cytokine	ADJ
ajst-26912	17	6	release	release	NOUN
ajst-26912	17	7	syndrome	syndrome	NOUN
ajst-26912	17	8	(	(	PUNCT
ajst-26912	17	9	crs	crs	PROPN
ajst-26912	17	10	)	)	PUNCT
ajst-26912	17	11	,	,	PUNCT
ajst-26912	17	12	neurotoxicity	neurotoxicity	NOUN
ajst-26912	17	13	,	,	PUNCT
ajst-26912	17	14	and	and	CCONJ
ajst-26912	17	15	persistent	persistent	ADJ
ajst-26912	17	16	immunodeficiency	immunodeficiency	NOUN
ajst-26912	17	17	,	,	PUNCT
ajst-26912	17	18	alongside	alongside	ADP
ajst-26912	17	19	risks	risk	NOUN
ajst-26912	17	20	in	in	ADP
ajst-26912	17	21	car	car	NOUN
ajst-26912	17	22	-	-	PUNCT
ajst-26912	17	23	t	t	NOUN
ajst-26912	17	24	preparation	preparation	NOUN
ajst-26912	17	25	,	,	PUNCT
ajst-26912	17	26	storage	storage	NOUN
ajst-26912	17	27	,	,	PUNCT
ajst-26912	17	28	and	and	CCONJ
ajst-26912	17	29	transport	transport	NOUN
ajst-26912	17	30	,	,	PUNCT
ajst-26912	17	31	pose	pose	VERB
ajst-26912	17	32	significant	significant	ADJ
ajst-26912	17	33	hurdles	hurdle	NOUN
ajst-26912	17	34	for	for	ADP
ajst-26912	17	35	further	further	ADJ
ajst-26912	17	36	development	development	NOUN
ajst-26912	18	1	[	[	X
ajst-26912	18	2	6	6	NUM
ajst-26912	18	3	]	]	PUNCT
ajst-26912	18	4	.	.	PUNCT
ajst-26912	19	1	balancing	balance	VERB
ajst-26912	19	2	efficacy	efficacy	NOUN
ajst-26912	19	3	with	with	ADP
ajst-26912	19	4	risk	risk	NOUN
ajst-26912	19	5	to	to	PART
ajst-26912	19	6	ensure	ensure	VERB
ajst-26912	19	7	patient	patient	ADJ
ajst-26912	19	8	safety	safety	NOUN
ajst-26912	19	9	is	be	AUX
ajst-26912	19	10	crucial	crucial	ADJ
ajst-26912	19	11	in	in	ADP
ajst-26912	19	12	car	car	NOUN
ajst-26912	19	13	-	-	PUNCT
ajst-26912	19	14	t	t	NOUN
ajst-26912	19	15	research	research	NOUN
ajst-26912	19	16	and	and	CCONJ
ajst-26912	19	17	application	application	NOUN
ajst-26912	19	18	.	.	PUNCT
ajst-26912	20	1	this	this	DET
ajst-26912	20	2	paper	paper	NOUN
ajst-26912	20	3	aims	aim	VERB
ajst-26912	20	4	to	to	PART
ajst-26912	20	5	consolidate	consolidate	VERB
ajst-26912	20	6	the	the	DET
ajst-26912	20	7	fundamental	fundamental	ADJ
ajst-26912	20	8	principles	principle	NOUN
ajst-26912	20	9	and	and	CCONJ
ajst-26912	20	10	clinical	clinical	ADJ
ajst-26912	20	11	uses	use	NOUN
ajst-26912	20	12	of	of	ADP
ajst-26912	20	13	car	car	NOUN
ajst-26912	20	14	-	-	PUNCT
ajst-26912	20	15	t	t	NOUN
ajst-26912	20	16	,	,	PUNCT
ajst-26912	20	17	emphasizing	emphasize	VERB
ajst-26912	20	18	recent	recent	ADJ
ajst-26912	20	19	progress	progress	NOUN
ajst-26912	20	20	in	in	ADP
ajst-26912	20	21	hematological	hematological	ADJ
ajst-26912	20	22	and	and	CCONJ
ajst-26912	20	23	solid	solid	ADJ
ajst-26912	20	24	tumor	tumor	NOUN
ajst-26912	20	25	treatment	treatment	NOUN
ajst-26912	20	26	.	.	PUNCT
ajst-26912	21	1	a	a	DET
ajst-26912	21	2	thorough	thorough	ADJ
ajst-26912	21	3	evaluation	evaluation	NOUN
ajst-26912	21	4	of	of	ADP
ajst-26912	21	5	car	car	NOUN
ajst-26912	21	6	-	-	PUNCT
ajst-26912	21	7	t	t	PROPN
ajst-26912	21	8	's	's	PART
ajst-26912	21	9	efficacy	efficacy	NOUN
ajst-26912	21	10	and	and	CCONJ
ajst-26912	21	11	risks	risk	NOUN
ajst-26912	21	12	will	will	AUX
ajst-26912	21	13	inform	inform	VERB
ajst-26912	21	14	clinical	clinical	ADJ
ajst-26912	21	15	decisions	decision	NOUN
ajst-26912	21	16	and	and	CCONJ
ajst-26912	21	17	offer	offer	VERB
ajst-26912	21	18	patients	patient	NOUN
ajst-26912	21	19	more	more	ADV
ajst-26912	21	20	effective	effective	ADJ
ajst-26912	21	21	treatment	treatment	NOUN
ajst-26912	21	22	alternatives	alternative	NOUN
ajst-26912	21	23	.	.	PUNCT
ajst-26912	22	1	2	2	X
ajst-26912	22	2	.	.	NUM
ajst-26912	22	3	basic	basic	ADJ
ajst-26912	22	4	principle	principle	NOUN
ajst-26912	22	5	of	of	ADP
ajst-26912	22	6	car	car	NOUN
ajst-26912	22	7	-	-	PUNCT
ajst-26912	22	8	t	t	NOUN
ajst-26912	22	9	cell	cell	NOUN
ajst-26912	22	10	technology	technology	NOUN
ajst-26912	22	11	car	car	NOUN
ajst-26912	22	12	-	-	PUNCT
ajst-26912	22	13	t	t	NOUN
ajst-26912	22	14	cells	cell	NOUN
ajst-26912	22	15	,	,	PUNCT
ajst-26912	22	16	or	or	CCONJ
ajst-26912	22	17	chimeric	chimeric	ADJ
ajst-26912	22	18	antigen	antigen	ADJ
ajst-26912	22	19	receptor	receptor	NOUN
ajst-26912	22	20	t	t	PROPN
ajst-26912	22	21	-	-	PUNCT
ajst-26912	22	22	cells	cell	NOUN
ajst-26912	22	23	,	,	PUNCT
ajst-26912	22	24	are	be	AUX
ajst-26912	22	25	genetically	genetically	ADV
ajst-26912	22	26	engineered	engineer	VERB
ajst-26912	22	27	t	t	NOUN
ajst-26912	22	28	lymphocytes	lymphocyte	NOUN
ajst-26912	22	29	designed	design	VERB
ajst-26912	22	30	to	to	PART
ajst-26912	22	31	recognize	recognize	VERB
ajst-26912	22	32	and	and	CCONJ
ajst-26912	22	33	bind	bind	VERB
ajst-26912	22	34	tumor	tumor	NOUN
ajst-26912	22	35	cell	cell	NOUN
ajst-26912	22	36	surface	surface	NOUN
ajst-26912	22	37	antigens	antigen	NOUN
ajst-26912	22	38	,	,	PUNCT
ajst-26912	22	39	activating	activate	VERB
ajst-26912	22	40	their	their	PRON
ajst-26912	22	41	killing	kill	VERB
ajst-26912	22	42	function	function	NOUN
ajst-26912	22	43	[	[	X
ajst-26912	22	44	7	7	NUM
ajst-26912	22	45	]	]	PUNCT
ajst-26912	22	46	.	.	PUNCT
ajst-26912	23	1	the	the	DET
ajst-26912	23	2	intricate	intricate	ADJ
ajst-26912	23	3	preparation	preparation	NOUN
ajst-26912	23	4	of	of	ADP
ajst-26912	23	5	car	car	NOUN
ajst-26912	23	6	-	-	PUNCT
ajst-26912	23	7	t	t	NOUN
ajst-26912	23	8	cells	cell	NOUN
ajst-26912	23	9	begins	begin	VERB
ajst-26912	23	10	with	with	ADP
ajst-26912	23	11	isolating	isolate	VERB
ajst-26912	23	12	t	t	NOUN
ajst-26912	23	13	lymphocytes	lymphocyte	NOUN
ajst-26912	23	14	from	from	ADP
ajst-26912	23	15	patient	patient	ADJ
ajst-26912	23	16	blood	blood	NOUN
ajst-26912	23	17	,	,	PUNCT
ajst-26912	23	18	which	which	PRON
ajst-26912	23	19	are	be	AUX
ajst-26912	23	20	vital	vital	ADJ
ajst-26912	23	21	for	for	ADP
ajst-26912	23	22	recognizing	recognize	VERB
ajst-26912	23	23	and	and	CCONJ
ajst-26912	23	24	attacking	attack	VERB
ajst-26912	23	25	foreign	foreign	ADJ
ajst-26912	23	26	invaders	invader	NOUN
ajst-26912	23	27	.	.	PUNCT
ajst-26912	24	1	using	use	VERB
ajst-26912	24	2	gene	gene	NOUN
ajst-26912	24	3	vectors	vector	NOUN
ajst-26912	24	4	,	,	PUNCT
ajst-26912	24	5	the	the	DET
ajst-26912	24	6	car	car	NOUN
ajst-26912	24	7	gene	gene	NOUN
ajst-26912	24	8	is	be	AUX
ajst-26912	24	9	then	then	ADV
ajst-26912	24	10	introduced	introduce	VERB
ajst-26912	24	11	into	into	ADP
ajst-26912	24	12	these	these	DET
ajst-26912	24	13	t	t	NOUN
ajst-26912	24	14	cells	cell	NOUN
ajst-26912	24	15	.	.	PUNCT
ajst-26912	25	1	following	follow	VERB
ajst-26912	25	2	a	a	DET
ajst-26912	25	3	series	series	NOUN
ajst-26912	25	4	of	of	ADP
ajst-26912	25	5	cultivation	cultivation	NOUN
ajst-26912	25	6	and	and	CCONJ
ajst-26912	25	7	screening	screening	NOUN
ajst-26912	25	8	,	,	PUNCT
ajst-26912	25	9	a	a	DET
ajst-26912	25	10	sufficient	sufficient	ADJ
ajst-26912	25	11	quantity	quantity	NOUN
ajst-26912	25	12	of	of	ADP
ajst-26912	25	13	car	car	NOUN
ajst-26912	25	14	-	-	PUNCT
ajst-26912	25	15	expressing	express	VERB
ajst-26912	25	16	t	t	NOUN
ajst-26912	25	17	cells	cell	NOUN
ajst-26912	25	18	is	be	AUX
ajst-26912	25	19	generated	generate	VERB
ajst-26912	25	20	and	and	CCONJ
ajst-26912	25	21	subsequently	subsequently	ADV
ajst-26912	25	22	infused	infuse	VERB
ajst-26912	25	23	into	into	ADP
ajst-26912	25	24	patients	patient	NOUN
ajst-26912	25	25	to	to	PART
ajst-26912	25	26	exert	exert	VERB
ajst-26912	25	27	their	their	PRON
ajst-26912	25	28	antitumor	antitumor	PROPN
ajst-26912	25	29	effects	effect	NOUN
ajst-26912	25	30	.	.	PUNCT
ajst-26912	26	1	the	the	DET
ajst-26912	26	2	car	car	NOUN
ajst-26912	26	3	-	-	PUNCT
ajst-26912	26	4	t	t	NOUN
ajst-26912	26	5	cell	cell	NOUN
ajst-26912	26	6	's	's	PART
ajst-26912	26	7	structure	structure	NOUN
ajst-26912	26	8	is	be	AUX
ajst-26912	26	9	integral	integral	ADJ
ajst-26912	26	10	to	to	ADP
ajst-26912	26	11	its	its	PRON
ajst-26912	26	12	function	function	NOUN
ajst-26912	26	13	,	,	PUNCT
ajst-26912	26	14	comprising	comprise	VERB
ajst-26912	26	15	four	four	NUM
ajst-26912	26	16	key	key	ADJ
ajst-26912	26	17	components	component	NOUN
ajst-26912	26	18	:	:	PUNCT
ajst-26912	26	19	the	the	DET
ajst-26912	26	20	extracellular	extracellular	ADJ
ajst-26912	26	21	antigenbinding	antigenbinding	NOUN
ajst-26912	26	22	domain	domain	NOUN
ajst-26912	26	23	,	,	PUNCT
ajst-26912	26	24	hinge	hinge	NOUN
ajst-26912	26	25	region	region	NOUN
ajst-26912	26	26	,	,	PUNCT
ajst-26912	26	27	transmembrane	transmembrane	ADJ
ajst-26912	26	28	region	region	NOUN
ajst-26912	26	29	,	,	PUNCT
ajst-26912	26	30	and	and	CCONJ
ajst-26912	26	31	intracellular	intracellular	ADJ
ajst-26912	26	32	signal	signal	NOUN
ajst-26912	26	33	region	region	NOUN
ajst-26912	26	34	.	.	PUNCT
ajst-26912	27	1	(	(	PUNCT
ajst-26912	27	2	1	1	X
ajst-26912	27	3	)	)	PUNCT
ajst-26912	27	4	the	the	DET
ajst-26912	27	5	extracellular	extracellular	ADJ
ajst-26912	27	6	antigen	antigen	NOUN
ajst-26912	27	7	-	-	PUNCT
ajst-26912	27	8	binding	bind	VERB
ajst-26912	27	9	domain	domain	NOUN
ajst-26912	27	10	,	,	PUNCT
ajst-26912	27	11	typically	typically	ADV
ajst-26912	27	12	a	a	DET
ajst-26912	27	13	single	single	ADJ
ajst-26912	27	14	-	-	PUNCT
ajst-26912	27	15	chain	chain	NOUN
ajst-26912	27	16	variable	variable	ADJ
ajst-26912	27	17	fragment	fragment	NOUN
ajst-26912	27	18	(	(	PUNCT
ajst-26912	27	19	scfv	scfv	PROPN
ajst-26912	27	20	)	)	PUNCT
ajst-26912	27	21	derived	derive	VERB
ajst-26912	27	22	from	from	ADP
ajst-26912	27	23	a	a	DET
ajst-26912	27	24	specific	specific	ADJ
ajst-26912	27	25	antigen	antigen	ADV
ajst-26912	27	26	-	-	PUNCT
ajst-26912	27	27	recognizing	recognize	VERB
ajst-26912	27	28	antibody	antibody	NOUN
ajst-26912	27	29	,	,	PUNCT
ajst-26912	27	30	binds	bind	VERB
ajst-26912	27	31	to	to	ADP
ajst-26912	27	32	tumor	tumor	NOUN
ajst-26912	27	33	cell	cell	NOUN
ajst-26912	27	34	surface	surface	NOUN
ajst-26912	27	35	antigens	antigen	NOUN
ajst-26912	27	36	.	.	PUNCT
ajst-26912	28	1	(	(	PUNCT
ajst-26912	28	2	2	2	X
ajst-26912	28	3	)	)	PUNCT
ajst-26912	28	4	the	the	DET
ajst-26912	28	5	hinge	hinge	NOUN
ajst-26912	28	6	region	region	NOUN
ajst-26912	28	7	connects	connect	VERB
ajst-26912	28	8	the	the	DET
ajst-26912	28	9	extracellular	extracellular	ADJ
ajst-26912	28	10	domain	domain	NOUN
ajst-26912	28	11	to	to	ADP
ajst-26912	28	12	the	the	DET
ajst-26912	28	13	transmembrane	transmembrane	NOUN
ajst-26912	28	14	region	region	NOUN
ajst-26912	28	15	,	,	PUNCT
ajst-26912	28	16	providing	provide	VERB
ajst-26912	28	17	support	support	NOUN
ajst-26912	28	18	.	.	PUNCT
ajst-26912	29	1	(	(	PUNCT
ajst-26912	29	2	3	3	X
ajst-26912	29	3	)	)	PUNCT
ajst-26912	29	4	the	the	DET
ajst-26912	29	5	transmembrane	transmembrane	NOUN
ajst-26912	29	6	region	region	NOUN
ajst-26912	29	7	,	,	PUNCT
ajst-26912	29	8	often	often	ADV
ajst-26912	29	9	sourced	source	VERB
ajst-26912	29	10	from	from	ADP
ajst-26912	29	11	t	t	PROPN
ajst-26912	29	12	cell	cell	NOUN
ajst-26912	29	13	surface	surface	NOUN
ajst-26912	29	14	molecules	molecule	NOUN
ajst-26912	29	15	like	like	ADP
ajst-26912	29	16	cd3ζ	cd3ζ	NOUN
ajst-26912	29	17	or	or	CCONJ
ajst-26912	29	18	cd28	cd28	PROPN
ajst-26912	29	19	,	,	PUNCT
ajst-26912	29	20	ensures	ensure	VERB
ajst-26912	29	21	stable	stable	ADJ
ajst-26912	29	22	car	car	NOUN
ajst-26912	29	23	anchoring	anchor	VERB
ajst-26912	29	24	on	on	ADP
ajst-26912	29	25	the	the	DET
ajst-26912	29	26	t	t	NOUN
ajst-26912	29	27	cell	cell	NOUN
ajst-26912	29	28	membrane	membrane	NOUN
ajst-26912	29	29	.	.	PUNCT
ajst-26912	30	1	(	(	PUNCT
ajst-26912	30	2	4	4	X
ajst-26912	30	3	)	)	PUNCT
ajst-26912	30	4	the	the	DET
ajst-26912	30	5	intracellular	intracellular	ADJ
ajst-26912	30	6	signal	signal	NOUN
ajst-26912	30	7	region	region	NOUN
ajst-26912	30	8	contains	contain	VERB
ajst-26912	30	9	signal	signal	NOUN
ajst-26912	30	10	transduction	transduction	NOUN
ajst-26912	30	11	domains	domain	NOUN
ajst-26912	30	12	from	from	ADP
ajst-26912	30	13	cd3ζ	cd3ζ	NOUN
ajst-26912	30	14	and/or	and/or	CCONJ
ajst-26912	30	15	costimulatory	costimulatory	ADJ
ajst-26912	30	16	molecules	molecule	NOUN
ajst-26912	30	17	(	(	PUNCT
ajst-26912	30	18	e.g.	e.g.	ADV
ajst-26912	30	19	,	,	PUNCT
ajst-26912	30	20	cd28	cd28	PROPN
ajst-26912	30	21	,	,	PUNCT
ajst-26912	30	22	4	4	NUM
ajst-26912	30	23	-	-	NUM
ajst-26912	30	24	1bb	1bb	NUM
ajst-26912	30	25	)	)	PUNCT
ajst-26912	30	26	,	,	PUNCT
ajst-26912	30	27	facilitating	facilitate	VERB
ajst-26912	30	28	car	car	NOUN
ajst-26912	30	29	-	-	PUNCT
ajst-26912	30	30	t	t	NOUN
ajst-26912	30	31	cell	cell	NOUN
ajst-26912	30	32	action	action	NOUN
ajst-26912	30	33	within	within	ADP
ajst-26912	30	34	t	t	NOUN
ajst-26912	30	35	cells	cell	NOUN
ajst-26912	30	36	.	.	PUNCT
ajst-26912	31	1	car	car	NOUN
ajst-26912	31	2	-	-	PUNCT
ajst-26912	31	3	t	t	NOUN
ajst-26912	31	4	cells	cell	NOUN
ajst-26912	31	5	operate	operate	VERB
ajst-26912	31	6	through	through	ADP
ajst-26912	31	7	two	two	NUM
ajst-26912	31	8	primary	primary	ADJ
ajst-26912	31	9	mechanisms	mechanism	NOUN
ajst-26912	31	10	:	:	PUNCT
ajst-26912	31	11	specific	specific	ADJ
ajst-26912	31	12	tumor	tumor	NOUN
ajst-26912	31	13	cell	cell	NOUN
ajst-26912	31	14	recognition	recognition	NOUN
ajst-26912	31	15	and	and	CCONJ
ajst-26912	31	16	killing	killing	NOUN
ajst-26912	31	17	,	,	PUNCT
ajst-26912	31	18	and	and	CCONJ
ajst-26912	31	19	immune	immune	ADJ
ajst-26912	31	20	system	system	NOUN
ajst-26912	31	21	activation	activation	NOUN
ajst-26912	31	22	.	.	PUNCT
ajst-26912	32	1	(	(	PUNCT
ajst-26912	32	2	1	1	NUM
ajst-26912	32	3	)	)	PUNCT
ajst-26912	32	4	upon	upon	SCONJ
ajst-26912	32	5	entering	enter	VERB
ajst-26912	32	6	the	the	DET
ajst-26912	32	7	body	body	NOUN
ajst-26912	32	8	,	,	PUNCT
ajst-26912	32	9	car	car	NOUN
ajst-26912	32	10	-	-	PUNCT
ajst-26912	32	11	t	t	NOUN
ajst-26912	32	12	cells	cell	NOUN
ajst-26912	32	13	recognize	recognize	VERB
ajst-26912	32	14	and	and	CCONJ
ajst-26912	32	15	bind	bind	VERB
ajst-26912	32	16	to	to	ADP
ajst-26912	32	17	tumor	tumor	NOUN
ajst-26912	32	18	cell	cell	NOUN
ajst-26912	32	19	surface	surface	NOUN
ajst-26912	32	20	antigens	antigen	NOUN
ajst-26912	32	21	,	,	PUNCT
ajst-26912	32	22	initiating	initiate	VERB
ajst-26912	32	23	the	the	DET
ajst-26912	32	24	car	car	NOUN
ajst-26912	32	25	molecule	molecule	NOUN
ajst-26912	32	26	's	's	PART
ajst-26912	32	27	signal	signal	ADJ
ajst-26912	32	28	transduction	transduction	NOUN
ajst-26912	32	29	pathway	pathway	NOUN
ajst-26912	32	30	and	and	CCONJ
ajst-26912	32	31	activating	activate	VERB
ajst-26912	32	32	t	t	NOUN
ajst-26912	32	33	cells	cell	NOUN
ajst-26912	32	34	[	[	X
ajst-26912	32	35	8	8	NUM
ajst-26912	32	36	]	]	PUNCT
ajst-26912	32	37	.	.	PUNCT
ajst-26912	33	1	(	(	PUNCT
ajst-26912	33	2	2	2	X
ajst-26912	33	3	)	)	PUNCT
ajst-26912	33	4	beyond	beyond	ADP
ajst-26912	33	5	direct	direct	ADJ
ajst-26912	33	6	tumor	tumor	NOUN
ajst-26912	33	7	cell	cell	NOUN
ajst-26912	33	8	killing	killing	NOUN
ajst-26912	33	9	,	,	PUNCT
ajst-26912	33	10	car	car	NOUN
ajst-26912	33	11	-	-	PUNCT
ajst-26912	33	12	t	t	NOUN
ajst-26912	33	13	cells	cell	NOUN
ajst-26912	33	14	also	also	ADV
ajst-26912	33	15	204	204	NUM
ajst-26912	33	16	stimulate	stimulate	VERB
ajst-26912	33	17	the	the	DET
ajst-26912	33	18	immune	immune	ADJ
ajst-26912	33	19	system	system	NOUN
ajst-26912	33	20	by	by	ADP
ajst-26912	33	21	interacting	interact	VERB
ajst-26912	33	22	with	with	ADP
ajst-26912	33	23	tumor	tumor	NOUN
ajst-26912	33	24	cells	cell	NOUN
ajst-26912	33	25	and	and	CCONJ
ajst-26912	33	26	releasing	release	VERB
ajst-26912	33	27	killer	killer	NOUN
ajst-26912	33	28	molecules	molecule	NOUN
ajst-26912	33	29	that	that	PRON
ajst-26912	33	30	affect	affect	VERB
ajst-26912	33	31	surrounding	surround	VERB
ajst-26912	33	32	immune	immune	ADJ
ajst-26912	33	33	cells	cell	NOUN
ajst-26912	33	34	,	,	PUNCT
ajst-26912	33	35	such	such	ADJ
ajst-26912	33	36	as	as	ADP
ajst-26912	33	37	macrophages	macrophage	NOUN
ajst-26912	33	38	and	and	CCONJ
ajst-26912	33	39	natural	natural	ADJ
ajst-26912	33	40	killer	killer	NOUN
ajst-26912	33	41	cells	cell	NOUN
ajst-26912	33	42	[	[	X
ajst-26912	33	43	9	9	NUM
ajst-26912	33	44	]	]	PUNCT
ajst-26912	33	45	.	.	PUNCT
ajst-26912	34	1	3	3	X
ajst-26912	34	2	.	.	X
ajst-26912	34	3	clinical	clinical	ADJ
ajst-26912	34	4	application	application	NOUN
ajst-26912	34	5	of	of	ADP
ajst-26912	34	6	car	car	NOUN
ajst-26912	34	7	-	-	PUNCT
ajst-26912	34	8	t	t	NOUN
ajst-26912	34	9	cell	cell	NOUN
ajst-26912	34	10	technology	technology	NOUN
ajst-26912	34	11	3.1	3.1	NUM
ajst-26912	34	12	.	.	PUNCT
ajst-26912	35	1	hematological	hematological	ADJ
ajst-26912	35	2	tumor	tumor	NOUN
ajst-26912	35	3	therapy	therapy	NOUN
ajst-26912	35	4	hematological	hematological	ADJ
ajst-26912	35	5	tumors	tumor	NOUN
ajst-26912	35	6	,	,	PUNCT
ajst-26912	35	7	encompassing	encompass	VERB
ajst-26912	35	8	acute	acute	ADJ
ajst-26912	35	9	lymphoblastic	lymphoblastic	ADJ
ajst-26912	35	10	leukemia	leukemia	NOUN
ajst-26912	35	11	(	(	PUNCT
ajst-26912	35	12	all	all	ADV
ajst-26912	35	13	)	)	PUNCT
ajst-26912	35	14	,	,	PUNCT
ajst-26912	35	15	chronic	chronic	ADJ
ajst-26912	35	16	lymphocytic	lymphocytic	ADJ
ajst-26912	35	17	leukemia	leukemia	NOUN
ajst-26912	35	18	(	(	PUNCT
ajst-26912	35	19	cll	cll	PROPN
ajst-26912	35	20	)	)	PUNCT
ajst-26912	35	21	,	,	PUNCT
ajst-26912	35	22	and	and	CCONJ
ajst-26912	35	23	multiple	multiple	ADJ
ajst-26912	35	24	myeloma	myeloma	NOUN
ajst-26912	35	25	,	,	PUNCT
ajst-26912	35	26	represent	represent	VERB
ajst-26912	35	27	the	the	DET
ajst-26912	35	28	initial	initial	ADJ
ajst-26912	35	29	and	and	CCONJ
ajst-26912	35	30	most	most	ADV
ajst-26912	35	31	accomplished	accomplish	VERB
ajst-26912	35	32	domains	domain	NOUN
ajst-26912	35	33	of	of	ADP
ajst-26912	35	34	car	car	NOUN
ajst-26912	35	35	-	-	PUNCT
ajst-26912	35	36	t	t	NOUN
ajst-26912	35	37	cell	cell	NOUN
ajst-26912	35	38	technology	technology	NOUN
ajst-26912	35	39	application	application	NOUN
ajst-26912	35	40	.	.	PUNCT
ajst-26912	36	1	notably	notably	ADV
ajst-26912	36	2	,	,	PUNCT
ajst-26912	36	3	the	the	DET
ajst-26912	36	4	utilization	utilization	NOUN
ajst-26912	36	5	of	of	ADP
ajst-26912	36	6	car	car	NOUN
ajst-26912	36	7	-	-	PUNCT
ajst-26912	36	8	t	t	NOUN
ajst-26912	36	9	cell	cell	NOUN
ajst-26912	36	10	therapy	therapy	NOUN
ajst-26912	36	11	targeting	target	VERB
ajst-26912	36	12	the	the	DET
ajst-26912	36	13	cd19	cd19	PROPN
ajst-26912	36	14	antigen	antigen	NOUN
ajst-26912	36	15	stands	stand	VERB
ajst-26912	36	16	out	out	ADP
ajst-26912	36	17	prominently	prominently	ADV
ajst-26912	36	18	within	within	ADP
ajst-26912	36	19	this	this	DET
ajst-26912	36	20	realm	realm	NOUN
ajst-26912	36	21	.	.	PUNCT
ajst-26912	37	1	this	this	DET
ajst-26912	37	2	specific	specific	ADJ
ajst-26912	37	3	therapy	therapy	NOUN
ajst-26912	37	4	has	have	AUX
ajst-26912	37	5	garnered	garner	VERB
ajst-26912	37	6	significant	significant	ADJ
ajst-26912	37	7	attention	attention	NOUN
ajst-26912	37	8	due	due	ADP
ajst-26912	37	9	to	to	ADP
ajst-26912	37	10	its	its	PRON
ajst-26912	37	11	promising	promising	ADJ
ajst-26912	37	12	results	result	NOUN
ajst-26912	37	13	in	in	ADP
ajst-26912	37	14	treating	treat	VERB
ajst-26912	37	15	these	these	DET
ajst-26912	37	16	hematological	hematological	ADJ
ajst-26912	37	17	malignancies	malignancy	NOUN
ajst-26912	37	18	,	,	PUNCT
ajst-26912	37	19	marking	mark	VERB
ajst-26912	37	20	a	a	DET
ajst-26912	37	21	significant	significant	ADJ
ajst-26912	37	22	advancement	advancement	NOUN
ajst-26912	37	23	in	in	ADP
ajst-26912	37	24	the	the	DET
ajst-26912	37	25	field	field	NOUN
ajst-26912	37	26	of	of	ADP
ajst-26912	37	27	cancer	cancer	NOUN
ajst-26912	37	28	immunotherapy	immunotherapy	NOUN
ajst-26912	37	29	.	.	PUNCT
ajst-26912	38	1	table	table	NOUN
ajst-26912	38	2	1	1	NUM
ajst-26912	38	3	.	.	PUNCT
ajst-26912	38	4	application	application	NOUN
ajst-26912	38	5	of	of	ADP
ajst-26912	38	6	cd19	cd19	PROPN
ajst-26912	38	7	-	-	PUNCT
ajst-26912	38	8	targeted	target	VERB
ajst-26912	38	9	car	car	NOUN
ajst-26912	38	10	-	-	PUNCT
ajst-26912	38	11	t	t	NOUN
ajst-26912	38	12	cell	cell	NOUN
ajst-26912	38	13	therapy	therapy	NOUN
ajst-26912	38	14	in	in	ADP
ajst-26912	38	15	hematologic	hematologic	ADJ
ajst-26912	38	16	malignancies	malignancy	NOUN
ajst-26912	38	17	tumor	tumor	NOUN
ajst-26912	38	18	type	type	NOUN
ajst-26912	38	19	clinical	clinical	ADJ
ajst-26912	38	20	trial	trial	NOUN
ajst-26912	38	21	phase	phase	NOUN
ajst-26912	38	22	efficacy	efficacy	NOUN
ajst-26912	38	23	overview	overview	NOUN
ajst-26912	38	24	acute	acute	NOUN
ajst-26912	38	25	lymphoblastic	lymphoblastic	ADJ
ajst-26912	38	26	leukemia	leukemia	NOUN
ajst-26912	38	27	(	(	PUNCT
ajst-26912	38	28	all	all	DET
ajst-26912	38	29	)	)	PUNCT
ajst-26912	38	30	phase	phase	NOUN
ajst-26912	38	31	iii	iii	NUM
ajst-26912	38	32	high	high	ADJ
ajst-26912	38	33	complete	complete	ADJ
ajst-26912	38	34	remission	remission	NOUN
ajst-26912	38	35	rates	rate	NOUN
ajst-26912	38	36	,	,	PUNCT
ajst-26912	38	37	significant	significant	ADJ
ajst-26912	38	38	improvement	improvement	NOUN
ajst-26912	38	39	in	in	ADP
ajst-26912	38	40	long	long	ADJ
ajst-26912	38	41	-	-	PUNCT
ajst-26912	38	42	term	term	NOUN
ajst-26912	38	43	survival	survival	NOUN
ajst-26912	38	44	,	,	PUNCT
ajst-26912	38	45	particularly	particularly	ADV
ajst-26912	38	46	for	for	ADP
ajst-26912	38	47	refractory	refractory	NOUN
ajst-26912	38	48	or	or	CCONJ
ajst-26912	38	49	relapsed	relapse	VERB
ajst-26912	38	50	patients	patient	NOUN
ajst-26912	38	51	chronic	chronic	VERB
ajst-26912	38	52	lymphocytic	lymphocytic	ADJ
ajst-26912	38	53	leukemia	leukemia	NOUN
ajst-26912	38	54	(	(	PUNCT
ajst-26912	38	55	cll	cll	NOUN
ajst-26912	38	56	)	)	PUNCT
ajst-26912	38	57	phase	phase	NOUN
ajst-26912	38	58	ii	ii	PROPN
ajst-26912	38	59	/	/	SYM
ajst-26912	38	60	iii	iii	NUM
ajst-26912	38	61	high	high	ADJ
ajst-26912	38	62	effective	effective	ADJ
ajst-26912	38	63	remission	remission	NOUN
ajst-26912	38	64	rates	rate	NOUN
ajst-26912	38	65	,	,	PUNCT
ajst-26912	38	66	especially	especially	ADV
ajst-26912	38	67	for	for	ADP
ajst-26912	38	68	patients	patient	NOUN
ajst-26912	38	69	with	with	ADP
ajst-26912	38	70	chemotherapy	chemotherapy	NOUN
ajst-26912	38	71	failure	failure	NOUN
ajst-26912	38	72	or	or	CCONJ
ajst-26912	38	73	relapse	relapse	VERB
ajst-26912	38	74	multiple	multiple	ADJ
ajst-26912	38	75	myeloma	myeloma	NOUN
ajst-26912	38	76	phase	phase	PROPN
ajst-26912	38	77	ii	ii	PROPN
ajst-26912	38	78	/	/	SYM
ajst-26912	38	79	iii	iii	NOUN
ajst-26912	38	80	significantly	significantly	ADV
ajst-26912	38	81	prolonged	prolonged	ADJ
ajst-26912	38	82	progression	progression	NOUN
ajst-26912	38	83	-	-	PUNCT
ajst-26912	38	84	free	free	ADJ
ajst-26912	38	85	survival	survival	NOUN
ajst-26912	38	86	,	,	PUNCT
ajst-26912	38	87	improved	improve	VERB
ajst-26912	38	88	overall	overall	ADJ
ajst-26912	38	89	survival	survival	NOUN
ajst-26912	38	90	table	table	NOUN
ajst-26912	38	91	1	1	NUM
ajst-26912	38	92	demonstrates	demonstrate	VERB
ajst-26912	38	93	that	that	SCONJ
ajst-26912	38	94	cd19	cd19	PROPN
ajst-26912	38	95	-	-	PUNCT
ajst-26912	38	96	directed	direct	VERB
ajst-26912	38	97	car	car	NOUN
ajst-26912	38	98	-	-	PUNCT
ajst-26912	38	99	t	t	NOUN
ajst-26912	38	100	cell	cell	NOUN
ajst-26912	38	101	therapy	therapy	NOUN
ajst-26912	38	102	has	have	AUX
ajst-26912	38	103	yielded	yield	VERB
ajst-26912	38	104	impressive	impressive	ADJ
ajst-26912	38	105	outcomes	outcome	NOUN
ajst-26912	38	106	across	across	ADP
ajst-26912	38	107	all	all	PRON
ajst-26912	38	108	,	,	PUNCT
ajst-26912	38	109	cll	cll	PROPN
ajst-26912	38	110	,	,	PUNCT
ajst-26912	38	111	and	and	CCONJ
ajst-26912	38	112	multiple	multiple	ADJ
ajst-26912	38	113	myeloma	myeloma	NOUN
ajst-26912	38	114	treatments	treatment	NOUN
ajst-26912	38	115	.	.	PUNCT
ajst-26912	39	1	notably	notably	ADV
ajst-26912	39	2	,	,	PUNCT
ajst-26912	39	3	numerous	numerous	ADJ
ajst-26912	39	4	clinical	clinical	ADJ
ajst-26912	39	5	trials	trial	NOUN
ajst-26912	39	6	highlight	highlight	VERB
ajst-26912	39	7	car	car	NOUN
ajst-26912	39	8	-	-	PUNCT
ajst-26912	39	9	t	t	PROPN
ajst-26912	39	10	's	's	PART
ajst-26912	39	11	capacity	capacity	NOUN
ajst-26912	39	12	to	to	PART
ajst-26912	39	13	induce	induce	VERB
ajst-26912	39	14	a	a	DET
ajst-26912	39	15	substantial	substantial	ADJ
ajst-26912	39	16	rate	rate	NOUN
ajst-26912	39	17	of	of	ADP
ajst-26912	39	18	complete	complete	ADJ
ajst-26912	39	19	remission	remission	NOUN
ajst-26912	39	20	in	in	ADP
ajst-26912	39	21	all	all	DET
ajst-26912	39	22	patients	patient	NOUN
ajst-26912	39	23	,	,	PUNCT
ajst-26912	39	24	consequently	consequently	ADV
ajst-26912	39	25	enhancing	enhance	VERB
ajst-26912	39	26	their	their	PRON
ajst-26912	39	27	long	long	ADJ
ajst-26912	39	28	-	-	PUNCT
ajst-26912	39	29	term	term	NOUN
ajst-26912	39	30	survival	survival	NOUN
ajst-26912	39	31	rates	rate	NOUN
ajst-26912	39	32	.	.	PUNCT
ajst-26912	40	1	for	for	ADP
ajst-26912	40	2	cll	cll	PROPN
ajst-26912	40	3	patients	patient	NOUN
ajst-26912	40	4	,	,	PUNCT
ajst-26912	40	5	particularly	particularly	ADV
ajst-26912	40	6	those	those	PRON
ajst-26912	40	7	experiencing	experience	VERB
ajst-26912	40	8	chemotherapy	chemotherapy	NOUN
ajst-26912	40	9	failure	failure	NOUN
ajst-26912	40	10	or	or	CCONJ
ajst-26912	40	11	relapse	relapse	NOUN
ajst-26912	40	12	,	,	PUNCT
ajst-26912	40	13	car	car	NOUN
ajst-26912	40	14	-	-	PUNCT
ajst-26912	40	15	t	t	NOUN
ajst-26912	40	16	cell	cell	NOUN
ajst-26912	40	17	therapy	therapy	NOUN
ajst-26912	40	18	has	have	AUX
ajst-26912	40	19	exhibited	exhibit	VERB
ajst-26912	40	20	a	a	DET
ajst-26912	40	21	markedly	markedly	ADV
ajst-26912	40	22	effective	effective	ADJ
ajst-26912	40	23	remission	remission	NOUN
ajst-26912	40	24	rate	rate	NOUN
ajst-26912	40	25	.	.	PUNCT
ajst-26912	41	1	moreover	moreover	ADV
ajst-26912	41	2	,	,	PUNCT
ajst-26912	41	3	in	in	ADP
ajst-26912	41	4	the	the	DET
ajst-26912	41	5	context	context	NOUN
ajst-26912	41	6	of	of	ADP
ajst-26912	41	7	multiple	multiple	ADJ
ajst-26912	41	8	myeloma	myeloma	NOUN
ajst-26912	41	9	,	,	PUNCT
ajst-26912	41	10	car	car	NOUN
ajst-26912	41	11	-	-	PUNCT
ajst-26912	41	12	t	t	NOUN
ajst-26912	41	13	cell	cell	NOUN
ajst-26912	41	14	therapy	therapy	NOUN
ajst-26912	41	15	has	have	AUX
ajst-26912	41	16	proven	prove	VERB
ajst-26912	41	17	capable	capable	ADJ
ajst-26912	41	18	of	of	ADP
ajst-26912	41	19	significantly	significantly	ADV
ajst-26912	41	20	extending	extend	VERB
ajst-26912	41	21	patients	patient	NOUN
ajst-26912	41	22	'	'	PART
ajst-26912	41	23	progression	progression	NOUN
ajst-26912	41	24	-	-	PUNCT
ajst-26912	41	25	free	free	ADJ
ajst-26912	41	26	survival	survival	NOUN
ajst-26912	41	27	while	while	SCONJ
ajst-26912	41	28	also	also	ADV
ajst-26912	41	29	boosting	boost	VERB
ajst-26912	41	30	their	their	PRON
ajst-26912	41	31	overall	overall	ADJ
ajst-26912	41	32	survival	survival	NOUN
ajst-26912	41	33	rates	rate	NOUN
ajst-26912	41	34	.	.	PUNCT
ajst-26912	42	1	3.2	3.2	NUM
ajst-26912	42	2	.	.	PUNCT
ajst-26912	42	3	treatment	treatment	NOUN
ajst-26912	42	4	of	of	ADP
ajst-26912	42	5	solid	solid	ADJ
ajst-26912	42	6	tumor	tumor	NOUN
ajst-26912	42	7	despite	despite	SCONJ
ajst-26912	42	8	car	car	NOUN
ajst-26912	42	9	-	-	PUNCT
ajst-26912	42	10	t	t	PROPN
ajst-26912	42	11	cell	cell	NOUN
ajst-26912	42	12	technology	technology	NOUN
ajst-26912	42	13	's	's	PART
ajst-26912	42	14	notable	notable	ADJ
ajst-26912	42	15	advancements	advancement	NOUN
ajst-26912	42	16	in	in	ADP
ajst-26912	42	17	hematological	hematological	ADJ
ajst-26912	42	18	tumor	tumor	NOUN
ajst-26912	42	19	treatment	treatment	NOUN
ajst-26912	42	20	,	,	PUNCT
ajst-26912	42	21	its	its	PRON
ajst-26912	42	22	utilization	utilization	NOUN
ajst-26912	42	23	for	for	ADP
ajst-26912	42	24	solid	solid	ADJ
ajst-26912	42	25	tumors	tumor	NOUN
ajst-26912	42	26	encounters	encounter	VERB
ajst-26912	42	27	numerous	numerous	ADJ
ajst-26912	42	28	hurdles	hurdle	NOUN
ajst-26912	42	29	.	.	PUNCT
ajst-26912	43	1	solid	solid	ADJ
ajst-26912	43	2	tumors	tumor	NOUN
ajst-26912	43	3	exhibit	exhibit	VERB
ajst-26912	43	4	more	more	ADV
ajst-26912	43	5	complex	complex	ADJ
ajst-26912	43	6	antigen	antigen	ADJ
ajst-26912	43	7	expression	expression	NOUN
ajst-26912	43	8	and	and	CCONJ
ajst-26912	43	9	a	a	DET
ajst-26912	43	10	harsher	harsh	ADJ
ajst-26912	43	11	microenvironment	microenvironment	NOUN
ajst-26912	43	12	,	,	PUNCT
ajst-26912	43	13	resulting	result	VERB
ajst-26912	43	14	in	in	ADP
ajst-26912	43	15	diminished	diminished	ADJ
ajst-26912	43	16	penetration	penetration	NOUN
ajst-26912	43	17	,	,	PUNCT
ajst-26912	43	18	survival	survival	NOUN
ajst-26912	43	19	,	,	PUNCT
ajst-26912	43	20	and	and	CCONJ
ajst-26912	43	21	cytotoxicity	cytotoxicity	NOUN
ajst-26912	43	22	of	of	ADP
ajst-26912	43	23	car	car	NOUN
ajst-26912	43	24	-	-	PUNCT
ajst-26912	43	25	t	t	NOUN
ajst-26912	43	26	cells	cell	NOUN
ajst-26912	43	27	.	.	PUNCT
ajst-26912	44	1	currently	currently	ADV
ajst-26912	44	2	,	,	PUNCT
ajst-26912	44	3	car	car	NOUN
ajst-26912	44	4	-	-	PUNCT
ajst-26912	44	5	t	t	NOUN
ajst-26912	44	6	cell	cell	NOUN
ajst-26912	44	7	therapy	therapy	NOUN
ajst-26912	44	8	for	for	ADP
ajst-26912	44	9	diverse	diverse	ADJ
ajst-26912	44	10	solid	solid	ADJ
ajst-26912	44	11	tumors	tumor	NOUN
ajst-26912	44	12	,	,	PUNCT
ajst-26912	44	13	including	include	VERB
ajst-26912	44	14	ovarian	ovarian	ADJ
ajst-26912	44	15	cancer	cancer	NOUN
ajst-26912	44	16	and	and	CCONJ
ajst-26912	44	17	renal	renal	ADJ
ajst-26912	44	18	cell	cell	NOUN
ajst-26912	44	19	carcinoma	carcinoma	NOUN
ajst-26912	44	20	,	,	PUNCT
ajst-26912	44	21	is	be	AUX
ajst-26912	44	22	undergoing	undergo	VERB
ajst-26912	44	23	clinical	clinical	ADJ
ajst-26912	44	24	trials	trial	NOUN
ajst-26912	44	25	.	.	PUNCT
ajst-26912	45	1	while	while	SCONJ
ajst-26912	45	2	therapeutic	therapeutic	ADJ
ajst-26912	45	3	efficacy	efficacy	NOUN
ajst-26912	45	4	requires	require	VERB
ajst-26912	45	5	further	further	ADJ
ajst-26912	45	6	validation	validation	NOUN
ajst-26912	45	7	,	,	PUNCT
ajst-26912	45	8	preliminary	preliminary	ADJ
ajst-26912	45	9	findings	finding	NOUN
ajst-26912	45	10	are	be	AUX
ajst-26912	45	11	promising	promise	VERB
ajst-26912	45	12	.	.	PUNCT
ajst-26912	46	1	specifically	specifically	ADV
ajst-26912	46	2	,	,	PUNCT
ajst-26912	46	3	in	in	ADP
ajst-26912	46	4	treating	treat	VERB
ajst-26912	46	5	certain	certain	ADJ
ajst-26912	46	6	ovarian	ovarian	ADJ
ajst-26912	46	7	cancer	cancer	NOUN
ajst-26912	46	8	patients	patient	NOUN
ajst-26912	46	9	,	,	PUNCT
ajst-26912	46	10	cart	cart	NOUN
ajst-26912	46	11	cell	cell	NOUN
ajst-26912	46	12	therapy	therapy	NOUN
ajst-26912	46	13	demonstrates	demonstrate	VERB
ajst-26912	46	14	antitumor	antitumor	PROPN
ajst-26912	46	15	activity	activity	NOUN
ajst-26912	46	16	and	and	CCONJ
ajst-26912	46	17	extends	extend	VERB
ajst-26912	46	18	patient	patient	ADJ
ajst-26912	46	19	survival	survival	NOUN
ajst-26912	46	20	.	.	PUNCT
ajst-26912	47	1	table	table	NOUN
ajst-26912	47	2	2	2	NUM
ajst-26912	47	3	.	.	PUNCT
ajst-26912	48	1	exploration	exploration	NOUN
ajst-26912	48	2	of	of	ADP
ajst-26912	48	3	car	car	NOUN
ajst-26912	48	4	-	-	PUNCT
ajst-26912	48	5	t	t	NOUN
ajst-26912	48	6	cell	cell	NOUN
ajst-26912	48	7	therapy	therapy	NOUN
ajst-26912	48	8	in	in	ADP
ajst-26912	48	9	solid	solid	ADJ
ajst-26912	48	10	tumors	tumor	NOUN
ajst-26912	48	11	tumor	tumor	NOUN
ajst-26912	48	12	type	type	NOUN
ajst-26912	48	13	clinical	clinical	ADJ
ajst-26912	48	14	trial	trial	NOUN
ajst-26912	48	15	phase	phase	NOUN
ajst-26912	48	16	preliminary	preliminary	ADJ
ajst-26912	48	17	efficacy	efficacy	NOUN
ajst-26912	48	18	overview	overview	NOUN
ajst-26912	48	19	ovarian	ovarian	ADJ
ajst-26912	48	20	cancer	cancer	NOUN
ajst-26912	48	21	phase	phase	NOUN
ajst-26912	48	22	i	i	PRON
ajst-26912	48	23	/	/	SYM
ajst-26912	48	24	ii	ii	PROPN
ajst-26912	48	25	demonstrated	demonstrate	VERB
ajst-26912	48	26	anti	anti	ADJ
ajst-26912	48	27	-	-	ADJ
ajst-26912	48	28	tumor	tumor	ADJ
ajst-26912	48	29	activity	activity	NOUN
ajst-26912	48	30	,	,	PUNCT
ajst-26912	48	31	prolonged	prolonged	ADJ
ajst-26912	48	32	survival	survival	NOUN
ajst-26912	48	33	renal	renal	ADJ
ajst-26912	48	34	cell	cell	NOUN
ajst-26912	48	35	carcinoma	carcinoma	NOUN
ajst-26912	48	36	phase	phase	NOUN
ajst-26912	48	37	i	i	PRON
ajst-26912	48	38	/	/	SYM
ajst-26912	48	39	ii	ii	PROPN
ajst-26912	48	40	tumor	tumor	NOUN
ajst-26912	48	41	reduction	reduction	NOUN
ajst-26912	48	42	observed	observe	VERB
ajst-26912	48	43	in	in	ADP
ajst-26912	48	44	some	some	DET
ajst-26912	48	45	patients	patient	NOUN
ajst-26912	48	46	,	,	PUNCT
ajst-26912	48	47	further	further	ADJ
ajst-26912	48	48	efficacy	efficacy	NOUN
ajst-26912	48	49	validation	validation	NOUN
ajst-26912	48	50	needed	need	VERB
ajst-26912	48	51	tumor	tumor	NOUN
ajst-26912	48	52	type	type	NOUN
ajst-26912	48	53	clinical	clinical	ADJ
ajst-26912	48	54	trial	trial	NOUN
ajst-26912	48	55	phase	phase	NOUN
ajst-26912	48	56	preliminary	preliminary	ADJ
ajst-26912	48	57	efficacy	efficacy	NOUN
ajst-26912	48	58	overview	overview	NOUN
ajst-26912	48	59	as	as	SCONJ
ajst-26912	48	60	depicted	depict	VERB
ajst-26912	48	61	in	in	ADP
ajst-26912	48	62	table	table	NOUN
ajst-26912	48	63	2	2	NUM
ajst-26912	48	64	,	,	PUNCT
ajst-26912	48	65	clinical	clinical	ADJ
ajst-26912	48	66	trials	trial	NOUN
ajst-26912	48	67	are	be	AUX
ajst-26912	48	68	currently	currently	ADV
ajst-26912	48	69	assessing	assess	VERB
ajst-26912	48	70	the	the	DET
ajst-26912	48	71	potential	potential	NOUN
ajst-26912	48	72	of	of	ADP
ajst-26912	48	73	car	car	NOUN
ajst-26912	48	74	-	-	PUNCT
ajst-26912	48	75	t	t	NOUN
ajst-26912	48	76	cell	cell	NOUN
ajst-26912	48	77	therapy	therapy	NOUN
ajst-26912	48	78	for	for	ADP
ajst-26912	48	79	treating	treat	VERB
ajst-26912	48	80	solid	solid	ADJ
ajst-26912	48	81	tumors	tumor	NOUN
ajst-26912	48	82	,	,	PUNCT
ajst-26912	48	83	including	include	VERB
ajst-26912	48	84	ovarian	ovarian	ADJ
ajst-26912	48	85	cancer	cancer	NOUN
ajst-26912	48	86	and	and	CCONJ
ajst-26912	48	87	renal	renal	ADJ
ajst-26912	48	88	cell	cell	NOUN
ajst-26912	48	89	carcinoma	carcinoma	NOUN
ajst-26912	48	90	,	,	PUNCT
ajst-26912	48	91	with	with	SCONJ
ajst-26912	48	92	early	early	ADJ
ajst-26912	48	93	signs	sign	NOUN
ajst-26912	48	94	of	of	ADP
ajst-26912	48	95	effectiveness	effectiveness	NOUN
ajst-26912	48	96	noted	note	VERB
ajst-26912	48	97	.	.	PUNCT
ajst-26912	49	1	although	although	SCONJ
ajst-26912	49	2	these	these	DET
ajst-26912	49	3	initial	initial	ADJ
ajst-26912	49	4	findings	finding	NOUN
ajst-26912	49	5	require	require	VERB
ajst-26912	49	6	additional	additional	ADJ
ajst-26912	49	7	confirmation	confirmation	NOUN
ajst-26912	49	8	,	,	PUNCT
ajst-26912	49	9	they	they	PRON
ajst-26912	49	10	offer	offer	VERB
ajst-26912	49	11	invaluable	invaluable	ADJ
ajst-26912	49	12	understanding	understanding	NOUN
ajst-26912	49	13	and	and	CCONJ
ajst-26912	49	14	expertise	expertise	NOUN
ajst-26912	49	15	in	in	ADP
ajst-26912	49	16	utilizing	utilize	VERB
ajst-26912	49	17	car	car	NOUN
ajst-26912	49	18	-	-	PUNCT
ajst-26912	49	19	t	t	NOUN
ajst-26912	49	20	cell	cell	NOUN
ajst-26912	49	21	technology	technology	NOUN
ajst-26912	49	22	to	to	PART
ajst-26912	49	23	tackle	tackle	VERB
ajst-26912	49	24	the	the	DET
ajst-26912	49	25	complexities	complexity	NOUN
ajst-26912	49	26	of	of	ADP
ajst-26912	49	27	solid	solid	ADJ
ajst-26912	49	28	tumors	tumor	NOUN
ajst-26912	49	29	.	.	PUNCT
ajst-26912	50	1	the	the	DET
ajst-26912	50	2	continuing	continue	VERB
ajst-26912	50	3	investigation	investigation	NOUN
ajst-26912	50	4	highlights	highlight	VERB
ajst-26912	50	5	the	the	DET
ajst-26912	50	6	promising	promising	ADJ
ajst-26912	50	7	prospects	prospect	NOUN
ajst-26912	50	8	of	of	ADP
ajst-26912	50	9	car	car	NOUN
ajst-26912	50	10	-	-	PUNCT
ajst-26912	50	11	t	t	NOUN
ajst-26912	50	12	therapy	therapy	NOUN
ajst-26912	50	13	in	in	ADP
ajst-26912	50	14	broadening	broaden	VERB
ajst-26912	50	15	its	its	PRON
ajst-26912	50	16	applicability	applicability	NOUN
ajst-26912	50	17	from	from	ADP
ajst-26912	50	18	hematological	hematological	ADJ
ajst-26912	50	19	malignancies	malignancy	NOUN
ajst-26912	50	20	to	to	ADP
ajst-26912	50	21	solid	solid	ADJ
ajst-26912	50	22	tumors	tumor	NOUN
ajst-26912	50	23	,	,	PUNCT
ajst-26912	50	24	thus	thus	ADV
ajst-26912	50	25	setting	set	VERB
ajst-26912	50	26	the	the	DET
ajst-26912	50	27	stage	stage	NOUN
ajst-26912	50	28	for	for	ADP
ajst-26912	50	29	future	future	ADJ
ajst-26912	50	30	progress	progress	NOUN
ajst-26912	50	31	and	and	CCONJ
ajst-26912	50	32	enhancements	enhancement	NOUN
ajst-26912	50	33	in	in	ADP
ajst-26912	50	34	therapeutic	therapeutic	ADJ
ajst-26912	50	35	approaches	approach	NOUN
ajst-26912	50	36	.	.	PUNCT
ajst-26912	51	1	4	4	X
ajst-26912	51	2	.	.	X
ajst-26912	51	3	risk	risk	NOUN
ajst-26912	51	4	assessment	assessment	NOUN
ajst-26912	51	5	of	of	ADP
ajst-26912	51	6	car	car	NOUN
ajst-26912	51	7	-	-	PUNCT
ajst-26912	51	8	t	t	NOUN
ajst-26912	51	9	cell	cell	NOUN
ajst-26912	51	10	technology	technology	NOUN
ajst-26912	51	11	4.1	4.1	NUM
ajst-26912	51	12	.	.	PUNCT
ajst-26912	52	1	main	main	ADJ
ajst-26912	52	2	adverse	adverse	ADJ
ajst-26912	52	3	reactions	reaction	NOUN
ajst-26912	52	4	the	the	DET
ajst-26912	52	5	main	main	ADJ
ajst-26912	52	6	adverse	adverse	ADJ
ajst-26912	52	7	reactions	reaction	NOUN
ajst-26912	52	8	associated	associate	VERB
ajst-26912	52	9	with	with	ADP
ajst-26912	52	10	car	car	NOUN
ajst-26912	52	11	-	-	PUNCT
ajst-26912	52	12	t	t	NOUN
ajst-26912	52	13	cell	cell	NOUN
ajst-26912	52	14	therapy	therapy	NOUN
ajst-26912	52	15	include	include	VERB
ajst-26912	52	16	cytokine	cytokine	NOUN
ajst-26912	52	17	release	release	NOUN
ajst-26912	52	18	syndrome	syndrome	NOUN
ajst-26912	52	19	(	(	PUNCT
ajst-26912	52	20	crs	crs	PROPN
ajst-26912	52	21	)	)	PUNCT
ajst-26912	52	22	and	and	CCONJ
ajst-26912	52	23	immune	immune	ADJ
ajst-26912	52	24	effector	effector	NOUN
ajst-26912	52	25	cell	cell	NOUN
ajst-26912	52	26	-	-	PUNCT
ajst-26912	52	27	associated	associate	VERB
ajst-26912	52	28	neurotoxicity	neurotoxicity	NOUN
ajst-26912	52	29	syndrome	syndrome	NOUN
ajst-26912	52	30	(	(	PUNCT
ajst-26912	52	31	icans	ican	NOUN
ajst-26912	52	32	)	)	PUNCT
ajst-26912	52	33	.	.	PUNCT
ajst-26912	53	1	crs	crs	PROPN
ajst-26912	53	2	is	be	AUX
ajst-26912	53	3	characterized	characterize	VERB
ajst-26912	53	4	by	by	ADP
ajst-26912	53	5	a	a	DET
ajst-26912	53	6	systemic	systemic	ADJ
ajst-26912	53	7	inflammatory	inflammatory	ADJ
ajst-26912	53	8	cascade	cascade	NOUN
ajst-26912	53	9	,	,	PUNCT
ajst-26912	53	10	while	while	SCONJ
ajst-26912	53	11	icans	icans	AUX
ajst-26912	53	12	exhibits	exhibit	VERB
ajst-26912	53	13	neurotoxic	neurotoxic	ADJ
ajst-26912	53	14	impacts	impact	NOUN
ajst-26912	53	15	on	on	ADP
ajst-26912	53	16	the	the	DET
ajst-26912	53	17	central	central	ADJ
ajst-26912	53	18	and/or	and/or	CCONJ
ajst-26912	53	19	peripheral	peripheral	ADJ
ajst-26912	53	20	nervous	nervous	ADJ
ajst-26912	53	21	systems	system	NOUN
ajst-26912	53	22	.	.	PUNCT
ajst-26912	54	1	both	both	DET
ajst-26912	54	2	reactions	reaction	NOUN
ajst-26912	54	3	are	be	AUX
ajst-26912	54	4	mechanistically	mechanistically	ADV
ajst-26912	54	5	tied	tie	VERB
ajst-26912	54	6	to	to	ADP
ajst-26912	54	7	the	the	DET
ajst-26912	54	8	release	release	NOUN
ajst-26912	54	9	of	of	ADP
ajst-26912	54	10	cytokines	cytokine	NOUN
ajst-26912	54	11	subsequent	subsequent	ADJ
ajst-26912	54	12	to	to	ADP
ajst-26912	54	13	car	car	NOUN
ajst-26912	54	14	-	-	PUNCT
ajst-26912	54	15	t	t	NOUN
ajst-26912	54	16	cell	cell	NOUN
ajst-26912	54	17	activation	activation	NOUN
ajst-26912	54	18	,	,	PUNCT
ajst-26912	54	19	which	which	PRON
ajst-26912	54	20	may	may	AUX
ajst-26912	54	21	provoke	provoke	VERB
ajst-26912	54	22	a	a	DET
ajst-26912	54	23	systemic	systemic	ADJ
ajst-26912	54	24	inflammatory	inflammatory	ADJ
ajst-26912	54	25	response	response	NOUN
ajst-26912	54	26	and	and	CCONJ
ajst-26912	54	27	harm	harm	VERB
ajst-26912	54	28	the	the	DET
ajst-26912	54	29	nervous	nervous	ADJ
ajst-26912	54	30	system	system	NOUN
ajst-26912	54	31	.	.	PUNCT
ajst-26912	55	1	managing	manage	VERB
ajst-26912	55	2	these	these	DET
ajst-26912	55	3	reactions	reaction	NOUN
ajst-26912	55	4	poses	pose	VERB
ajst-26912	55	5	considerable	considerable	ADJ
ajst-26912	55	6	challenges	challenge	NOUN
ajst-26912	55	7	in	in	ADP
ajst-26912	55	8	the	the	DET
ajst-26912	55	9	care	care	NOUN
ajst-26912	55	10	of	of	ADP
ajst-26912	55	11	patients	patient	NOUN
ajst-26912	55	12	undergoing	undergo	VERB
ajst-26912	55	13	car	car	NOUN
ajst-26912	55	14	-	-	PUNCT
ajst-26912	55	15	t	t	NOUN
ajst-26912	55	16	cell	cell	NOUN
ajst-26912	55	17	therapy	therapy	NOUN
ajst-26912	55	18	.	.	PUNCT
ajst-26912	56	1	205	205	NUM
ajst-26912	56	2	table	table	NOUN
ajst-26912	56	3	3	3	NUM
ajst-26912	56	4	.	.	PUNCT
ajst-26912	56	5	major	major	ADJ
ajst-26912	56	6	adverse	adverse	ADJ
ajst-26912	56	7	reactions	reaction	NOUN
ajst-26912	56	8	of	of	ADP
ajst-26912	56	9	car	car	NOUN
ajst-26912	56	10	-	-	PUNCT
ajst-26912	56	11	t	t	NOUN
ajst-26912	56	12	cell	cell	NOUN
ajst-26912	56	13	therapy	therapy	NOUN
ajst-26912	56	14	adverse	adverse	ADJ
ajst-26912	56	15	reaction	reaction	NOUN
ajst-26912	56	16	type	type	NOUN
ajst-26912	56	17	description	description	NOUN
ajst-26912	56	18	incidence	incidence	NOUN
ajst-26912	56	19	rate	rate	NOUN
ajst-26912	56	20	cytokine	cytokine	NOUN
ajst-26912	56	21	release	release	NOUN
ajst-26912	56	22	syndrome	syndrome	NOUN
ajst-26912	56	23	(	(	PUNCT
ajst-26912	56	24	crs	crs	PROPN
ajst-26912	56	25	)	)	PUNCT
ajst-26912	56	26	a	a	DET
ajst-26912	56	27	systemic	systemic	ADJ
ajst-26912	56	28	inflammatory	inflammatory	ADJ
ajst-26912	56	29	response	response	NOUN
ajst-26912	56	30	caused	cause	VERB
ajst-26912	56	31	by	by	ADP
ajst-26912	56	32	the	the	DET
ajst-26912	56	33	massive	massive	ADJ
ajst-26912	56	34	release	release	NOUN
ajst-26912	56	35	of	of	ADP
ajst-26912	56	36	cytokines	cytokine	NOUN
ajst-26912	56	37	following	follow	VERB
ajst-26912	56	38	car	car	NOUN
ajst-26912	56	39	-	-	PUNCT
ajst-26912	56	40	t	t	NOUN
ajst-26912	56	41	cell	cell	NOUN
ajst-26912	56	42	activation	activation	NOUN
ajst-26912	56	43	,	,	PUNCT
ajst-26912	56	44	which	which	PRON
ajst-26912	56	45	may	may	AUX
ajst-26912	56	46	include	include	VERB
ajst-26912	56	47	fever	fever	NOUN
ajst-26912	56	48	,	,	PUNCT
ajst-26912	56	49	hypotension	hypotension	NOUN
ajst-26912	56	50	,	,	PUNCT
ajst-26912	56	51	dyspnea	dyspnea	NOUN
ajst-26912	56	52	,	,	PUNCT
ajst-26912	56	53	etc	etc	X
ajst-26912	56	54	.	.	X
ajst-26912	56	55	≥	≥	PROPN
ajst-26912	56	56	grade	grade	PROPN
ajst-26912	56	57	3	3	NUM
ajst-26912	56	58	crs	crs	PROPN
ajst-26912	56	59	:	:	PUNCT
ajst-26912	56	60	10%-30	10%-30	NUM
ajst-26912	56	61	%	%	NOUN
ajst-26912	56	62	immune	immune	ADJ
ajst-26912	56	63	effector	effector	NOUN
ajst-26912	56	64	cell	cell	NOUN
ajst-26912	56	65	-	-	PUNCT
ajst-26912	56	66	associated	associate	VERB
ajst-26912	56	67	neurotoxicity	neurotoxicity	NOUN
ajst-26912	56	68	syndrome	syndrome	NOUN
ajst-26912	56	69	(	(	PUNCT
ajst-26912	56	70	icans	ican	NOUN
ajst-26912	56	71	)	)	PUNCT
ajst-26912	56	72	involves	involve	VERB
ajst-26912	56	73	the	the	DET
ajst-26912	56	74	central	central	ADJ
ajst-26912	56	75	nervous	nervous	ADJ
ajst-26912	56	76	system	system	NOUN
ajst-26912	56	77	,	,	PUNCT
ajst-26912	56	78	with	with	ADP
ajst-26912	56	79	symptoms	symptom	NOUN
ajst-26912	56	80	including	include	VERB
ajst-26912	56	81	altered	alter	VERB
ajst-26912	56	82	mental	mental	ADJ
ajst-26912	56	83	status	status	NOUN
ajst-26912	56	84	,	,	PUNCT
ajst-26912	56	85	attention	attention	NOUN
ajst-26912	56	86	deficit	deficit	NOUN
ajst-26912	56	87	,	,	PUNCT
ajst-26912	56	88	headache	headache	NOUN
ajst-26912	56	89	,	,	PUNCT
ajst-26912	56	90	tremor	tremor	NOUN
ajst-26912	56	91	,	,	PUNCT
ajst-26912	56	92	behavioral	behavioral	ADJ
ajst-26912	56	93	changes	change	NOUN
ajst-26912	56	94	,	,	PUNCT
ajst-26912	56	95	seizures	seizure	NOUN
ajst-26912	56	96	,	,	PUNCT
ajst-26912	56	97	etc	etc	X
ajst-26912	56	98	.	.	X
ajst-26912	56	99	≥	≥	PROPN
ajst-26912	56	100	grade	grade	NOUN
ajst-26912	56	101	3	3	NUM
ajst-26912	56	102	icans	ican	NOUN
ajst-26912	56	103	:	:	PUNCT
ajst-26912	56	104	5%-26	5%-26	NUM
ajst-26912	56	105	%	%	NOUN
ajst-26912	56	106	table	table	NOUN
ajst-26912	56	107	3	3	NUM
ajst-26912	56	108	reveals	reveal	VERB
ajst-26912	56	109	that	that	SCONJ
ajst-26912	56	110	crs	crs	PROPN
ajst-26912	56	111	and	and	CCONJ
ajst-26912	56	112	icans	ican	NOUN
ajst-26912	56	113	are	be	AUX
ajst-26912	56	114	the	the	DET
ajst-26912	56	115	most	most	ADV
ajst-26912	56	116	common	common	ADJ
ajst-26912	56	117	and	and	CCONJ
ajst-26912	56	118	severe	severe	ADJ
ajst-26912	56	119	adverse	adverse	ADJ
ajst-26912	56	120	reactions	reaction	NOUN
ajst-26912	56	121	linked	link	VERB
ajst-26912	56	122	to	to	ADP
ajst-26912	56	123	car	car	NOUN
ajst-26912	56	124	-	-	PUNCT
ajst-26912	56	125	t	t	NOUN
ajst-26912	56	126	cell	cell	NOUN
ajst-26912	56	127	therapy	therapy	NOUN
ajst-26912	56	128	.	.	PUNCT
ajst-26912	57	1	various	various	ADJ
ajst-26912	57	2	factors	factor	NOUN
ajst-26912	57	3	,	,	PUNCT
ajst-26912	57	4	such	such	ADJ
ajst-26912	57	5	as	as	ADP
ajst-26912	57	6	the	the	DET
ajst-26912	57	7	car	car	NOUN
ajst-26912	57	8	-	-	PUNCT
ajst-26912	57	9	t	t	NOUN
ajst-26912	57	10	cell	cell	NOUN
ajst-26912	57	11	dose	dose	NOUN
ajst-26912	57	12	administered	administer	VERB
ajst-26912	57	13	,	,	PUNCT
ajst-26912	57	14	tumor	tumor	NOUN
ajst-26912	57	15	burden	burden	NOUN
ajst-26912	57	16	,	,	PUNCT
ajst-26912	57	17	and	and	CCONJ
ajst-26912	57	18	patient	patient	NOUN
ajst-26912	57	19	's	's	PART
ajst-26912	57	20	immune	immune	ADJ
ajst-26912	57	21	status	status	NOUN
ajst-26912	57	22	,	,	PUNCT
ajst-26912	57	23	significantly	significantly	ADV
ajst-26912	57	24	impact	impact	VERB
ajst-26912	57	25	the	the	DET
ajst-26912	57	26	incidence	incidence	NOUN
ajst-26912	57	27	and	and	CCONJ
ajst-26912	57	28	severity	severity	NOUN
ajst-26912	57	29	of	of	ADP
ajst-26912	57	30	these	these	DET
ajst-26912	57	31	reactions	reaction	NOUN
ajst-26912	57	32	.	.	PUNCT
ajst-26912	58	1	this	this	DET
ajst-26912	58	2	complex	complex	ADJ
ajst-26912	58	3	interplay	interplay	NOUN
ajst-26912	58	4	of	of	ADP
ajst-26912	58	5	factors	factor	NOUN
ajst-26912	58	6	emphasizes	emphasize	VERB
ajst-26912	58	7	the	the	DET
ajst-26912	58	8	need	need	NOUN
ajst-26912	58	9	for	for	ADP
ajst-26912	58	10	tailored	tailor	VERB
ajst-26912	58	11	treatment	treatment	NOUN
ajst-26912	58	12	strategies	strategy	NOUN
ajst-26912	58	13	and	and	CCONJ
ajst-26912	58	14	rigorous	rigorous	ADJ
ajst-26912	58	15	monitoring	monitoring	NOUN
ajst-26912	58	16	to	to	PART
ajst-26912	58	17	reduce	reduce	VERB
ajst-26912	58	18	risks	risk	NOUN
ajst-26912	58	19	and	and	CCONJ
ajst-26912	58	20	enhance	enhance	VERB
ajst-26912	58	21	the	the	DET
ajst-26912	58	22	safety	safety	NOUN
ajst-26912	58	23	of	of	ADP
ajst-26912	58	24	car	car	NOUN
ajst-26912	58	25	-	-	PUNCT
ajst-26912	58	26	t	t	NOUN
ajst-26912	58	27	cell	cell	NOUN
ajst-26912	58	28	therapy	therapy	NOUN
ajst-26912	58	29	.	.	PUNCT
ajst-26912	59	1	4.2	4.2	NUM
ajst-26912	59	2	.	.	PUNCT
ajst-26912	60	1	long	long	ADJ
ajst-26912	60	2	-	-	PUNCT
ajst-26912	60	3	term	term	NOUN
ajst-26912	60	4	security	security	NOUN
ajst-26912	60	5	issues	issue	NOUN
ajst-26912	60	6	in	in	ADP
ajst-26912	60	7	addition	addition	NOUN
ajst-26912	60	8	to	to	ADP
ajst-26912	60	9	the	the	DET
ajst-26912	60	10	short	short	ADJ
ajst-26912	60	11	-	-	PUNCT
ajst-26912	60	12	term	term	NOUN
ajst-26912	60	13	adverse	adverse	ADJ
ajst-26912	60	14	reactions	reaction	NOUN
ajst-26912	60	15	mentioned	mention	VERB
ajst-26912	60	16	above	above	ADV
ajst-26912	60	17	,	,	PUNCT
ajst-26912	60	18	car	car	NOUN
ajst-26912	60	19	-	-	PUNCT
ajst-26912	60	20	t	t	NOUN
ajst-26912	60	21	cell	cell	NOUN
ajst-26912	60	22	therapy	therapy	NOUN
ajst-26912	60	23	also	also	ADV
ajst-26912	60	24	has	have	VERB
ajst-26912	60	25	some	some	DET
ajst-26912	60	26	long	long	ADJ
ajst-26912	60	27	-	-	PUNCT
ajst-26912	60	28	term	term	NOUN
ajst-26912	60	29	safety	safety	NOUN
ajst-26912	60	30	problems	problem	NOUN
ajst-26912	60	31	.	.	PUNCT
ajst-26912	61	1	for	for	ADP
ajst-26912	61	2	example	example	NOUN
ajst-26912	61	3	,	,	PUNCT
ajst-26912	61	4	car	car	NOUN
ajst-26912	61	5	-	-	PUNCT
ajst-26912	61	6	t	t	NOUN
ajst-26912	61	7	cells	cell	NOUN
ajst-26912	61	8	may	may	AUX
ajst-26912	61	9	cause	cause	VERB
ajst-26912	61	10	persistent	persistent	ADJ
ajst-26912	61	11	immunosuppression	immunosuppression	NOUN
ajst-26912	61	12	or	or	CCONJ
ajst-26912	61	13	immune	immune	ADJ
ajst-26912	61	14	disorder	disorder	NOUN
ajst-26912	61	15	,	,	PUNCT
ajst-26912	61	16	increasing	increase	VERB
ajst-26912	61	17	the	the	DET
ajst-26912	61	18	risk	risk	NOUN
ajst-26912	61	19	of	of	ADP
ajst-26912	61	20	infection	infection	NOUN
ajst-26912	61	21	in	in	ADP
ajst-26912	61	22	patients	patient	NOUN
ajst-26912	61	23	.	.	PUNCT
ajst-26912	62	1	in	in	ADP
ajst-26912	62	2	addition	addition	NOUN
ajst-26912	62	3	,	,	PUNCT
ajst-26912	62	4	car	car	NOUN
ajst-26912	62	5	-	-	PUNCT
ajst-26912	62	6	t	t	NOUN
ajst-26912	62	7	cell	cell	NOUN
ajst-26912	62	8	therapy	therapy	NOUN
ajst-26912	62	9	may	may	AUX
ajst-26912	62	10	interact	interact	VERB
ajst-26912	62	11	with	with	ADP
ajst-26912	62	12	patients	patient	NOUN
ajst-26912	62	13	'	'	PART
ajst-26912	62	14	basic	basic	ADJ
ajst-26912	62	15	diseases	disease	NOUN
ajst-26912	62	16	or	or	CCONJ
ajst-26912	62	17	combined	combine	VERB
ajst-26912	62	18	medication	medication	NOUN
ajst-26912	62	19	,	,	PUNCT
ajst-26912	62	20	leading	lead	VERB
ajst-26912	62	21	to	to	ADP
ajst-26912	62	22	new	new	ADJ
ajst-26912	62	23	complications	complication	NOUN
ajst-26912	62	24	.	.	PUNCT
ajst-26912	63	1	more	more	ADV
ajst-26912	63	2	seriously	seriously	ADV
ajst-26912	63	3	,	,	PUNCT
ajst-26912	63	4	studies	study	NOUN
ajst-26912	63	5	have	have	AUX
ajst-26912	63	6	shown	show	VERB
ajst-26912	63	7	that	that	PRON
ajst-26912	63	8	car	car	NOUN
ajst-26912	63	9	-	-	PUNCT
ajst-26912	63	10	t	t	NOUN
ajst-26912	63	11	cell	cell	NOUN
ajst-26912	63	12	therapy	therapy	NOUN
ajst-26912	63	13	may	may	AUX
ajst-26912	63	14	increase	increase	VERB
ajst-26912	63	15	the	the	DET
ajst-26912	63	16	risk	risk	NOUN
ajst-26912	63	17	of	of	ADP
ajst-26912	63	18	secondary	secondary	ADJ
ajst-26912	63	19	malignant	malignant	ADJ
ajst-26912	63	20	tumor	tumor	NOUN
ajst-26912	63	21	.	.	PUNCT
ajst-26912	64	1	car	car	NOUN
ajst-26912	64	2	-	-	PUNCT
ajst-26912	64	3	t	t	NOUN
ajst-26912	64	4	cell	cell	NOUN
ajst-26912	64	5	therapy	therapy	NOUN
ajst-26912	64	6	targeting	target	VERB
ajst-26912	64	7	bcma	bcma	NOUN
ajst-26912	64	8	or	or	CCONJ
ajst-26912	64	9	cd19	cd19	PROPN
ajst-26912	64	10	has	have	AUX
ajst-26912	64	11	been	be	AUX
ajst-26912	64	12	reported	report	VERB
ajst-26912	64	13	to	to	PART
ajst-26912	64	14	be	be	AUX
ajst-26912	64	15	related	relate	VERB
ajst-26912	64	16	to	to	ADP
ajst-26912	64	17	the	the	DET
ajst-26912	64	18	occurrence	occurrence	NOUN
ajst-26912	64	19	of	of	ADP
ajst-26912	64	20	t	t	PROPN
ajst-26912	64	21	cell	cell	NOUN
ajst-26912	64	22	malignant	malignant	ADJ
ajst-26912	64	23	tumor	tumor	NOUN
ajst-26912	64	24	.	.	PUNCT
ajst-26912	65	1	although	although	SCONJ
ajst-26912	65	2	this	this	DET
ajst-26912	65	3	risk	risk	NOUN
ajst-26912	65	4	is	be	AUX
ajst-26912	65	5	relatively	relatively	ADV
ajst-26912	65	6	low	low	ADJ
ajst-26912	65	7	,	,	PUNCT
ajst-26912	65	8	it	it	PRON
ajst-26912	65	9	still	still	ADV
ajst-26912	65	10	needs	need	VERB
ajst-26912	65	11	to	to	PART
ajst-26912	65	12	be	be	AUX
ajst-26912	65	13	highly	highly	ADV
ajst-26912	65	14	valued	value	VERB
ajst-26912	65	15	.	.	PUNCT
ajst-26912	66	1	4.3	4.3	NUM
ajst-26912	66	2	.	.	PUNCT
ajst-26912	66	3	regulatory	regulatory	ADJ
ajst-26912	66	4	measures	measure	NOUN
ajst-26912	66	5	and	and	CCONJ
ajst-26912	66	6	risk	risk	NOUN
ajst-26912	66	7	management	management	NOUN
ajst-26912	66	8	considering	consider	VERB
ajst-26912	66	9	the	the	DET
ajst-26912	66	10	risks	risk	NOUN
ajst-26912	66	11	associated	associate	VERB
ajst-26912	66	12	with	with	ADP
ajst-26912	66	13	car	car	NOUN
ajst-26912	66	14	-	-	PUNCT
ajst-26912	66	15	t	t	NOUN
ajst-26912	66	16	cell	cell	NOUN
ajst-26912	66	17	therapy	therapy	NOUN
ajst-26912	66	18	,	,	PUNCT
ajst-26912	66	19	regulatory	regulatory	ADJ
ajst-26912	66	20	bodies	body	NOUN
ajst-26912	66	21	have	have	AUX
ajst-26912	66	22	implemented	implement	VERB
ajst-26912	66	23	numerous	numerous	ADJ
ajst-26912	66	24	measures	measure	NOUN
ajst-26912	66	25	to	to	PART
ajst-26912	66	26	safeguard	safeguard	VERB
ajst-26912	66	27	patient	patient	ADJ
ajst-26912	66	28	safety	safety	NOUN
ajst-26912	66	29	.	.	PUNCT
ajst-26912	67	1	an	an	DET
ajst-26912	67	2	example	example	NOUN
ajst-26912	67	3	is	be	AUX
ajst-26912	67	4	the	the	DET
ajst-26912	67	5	us	us	PROPN
ajst-26912	67	6	food	food	NOUN
ajst-26912	67	7	and	and	CCONJ
ajst-26912	67	8	drug	drug	PROPN
ajst-26912	67	9	administration	administration	PROPN
ajst-26912	67	10	(	(	PUNCT
ajst-26912	67	11	fda	fda	PROPN
ajst-26912	67	12	)	)	PUNCT
ajst-26912	67	13	,	,	PUNCT
ajst-26912	67	14	which	which	PRON
ajst-26912	67	15	mandates	mandate	VERB
ajst-26912	67	16	rigorous	rigorous	ADJ
ajst-26912	67	17	safety	safety	NOUN
ajst-26912	67	18	evaluations	evaluation	NOUN
ajst-26912	67	19	for	for	ADP
ajst-26912	67	20	car	car	NOUN
ajst-26912	67	21	-	-	PUNCT
ajst-26912	67	22	t	t	NOUN
ajst-26912	67	23	cell	cell	NOUN
ajst-26912	67	24	therapy	therapy	NOUN
ajst-26912	67	25	products	product	NOUN
ajst-26912	67	26	and	and	CCONJ
ajst-26912	67	27	ongoing	ongoing	ADJ
ajst-26912	67	28	monitoring	monitoring	NOUN
ajst-26912	67	29	of	of	ADP
ajst-26912	67	30	adverse	adverse	ADJ
ajst-26912	67	31	events	event	NOUN
ajst-26912	67	32	post	post	ADJ
ajst-26912	67	33	-	-	ADJ
ajst-26912	67	34	marketing	marketing	NOUN
ajst-26912	67	35	.	.	PUNCT
ajst-26912	68	1	at	at	ADP
ajst-26912	68	2	the	the	DET
ajst-26912	68	3	same	same	ADJ
ajst-26912	68	4	time	time	NOUN
ajst-26912	68	5	,	,	PUNCT
ajst-26912	68	6	fda	fda	PROPN
ajst-26912	68	7	also	also	ADV
ajst-26912	68	8	requires	require	VERB
ajst-26912	68	9	that	that	SCONJ
ajst-26912	68	10	the	the	DET
ajst-26912	68	11	potential	potential	ADJ
ajst-26912	68	12	risks	risk	NOUN
ajst-26912	68	13	and	and	CCONJ
ajst-26912	68	14	adverse	adverse	ADJ
ajst-26912	68	15	reactions	reaction	NOUN
ajst-26912	68	16	be	be	AUX
ajst-26912	68	17	clearly	clearly	ADV
ajst-26912	68	18	marked	mark	VERB
ajst-26912	68	19	in	in	ADP
ajst-26912	68	20	the	the	DET
ajst-26912	68	21	product	product	NOUN
ajst-26912	68	22	specifications	specification	NOUN
ajst-26912	68	23	,	,	PUNCT
ajst-26912	68	24	so	so	SCONJ
ajst-26912	68	25	that	that	SCONJ
ajst-26912	68	26	doctors	doctor	NOUN
ajst-26912	68	27	and	and	CCONJ
ajst-26912	68	28	patients	patient	NOUN
ajst-26912	68	29	can	can	AUX
ajst-26912	68	30	fully	fully	ADV
ajst-26912	68	31	understand	understand	VERB
ajst-26912	68	32	and	and	CCONJ
ajst-26912	68	33	make	make	VERB
ajst-26912	68	34	informed	informed	ADJ
ajst-26912	68	35	decisions	decision	NOUN
ajst-26912	68	36	.	.	PUNCT
ajst-26912	69	1	in	in	ADP
ajst-26912	69	2	china	china	PROPN
ajst-26912	69	3	,	,	PUNCT
ajst-26912	69	4	national	national	PROPN
ajst-26912	69	5	medical	medical	ADJ
ajst-26912	69	6	products	product	NOUN
ajst-26912	69	7	administration	administration	PROPN
ajst-26912	69	8	(	(	PUNCT
ajst-26912	69	9	nmpa	nmpa	PROPN
ajst-26912	69	10	)	)	PUNCT
ajst-26912	69	11	has	have	AUX
ajst-26912	69	12	also	also	ADV
ajst-26912	69	13	strengthened	strengthen	VERB
ajst-26912	69	14	the	the	DET
ajst-26912	69	15	supervision	supervision	NOUN
ajst-26912	69	16	of	of	ADP
ajst-26912	69	17	car	car	NOUN
ajst-26912	69	18	-	-	PUNCT
ajst-26912	69	19	t	t	NOUN
ajst-26912	69	20	cell	cell	NOUN
ajst-26912	69	21	therapy	therapy	NOUN
ajst-26912	69	22	products	product	NOUN
ajst-26912	69	23	.	.	PUNCT
ajst-26912	70	1	nmpa	nmpa	NOUN
ajst-26912	70	2	also	also	ADV
ajst-26912	70	3	organizes	organize	VERB
ajst-26912	70	4	experts	expert	NOUN
ajst-26912	70	5	to	to	PART
ajst-26912	70	6	conduct	conduct	VERB
ajst-26912	70	7	in	in	ADP
ajst-26912	70	8	-	-	PUNCT
ajst-26912	70	9	depth	depth	NOUN
ajst-26912	70	10	research	research	NOUN
ajst-26912	70	11	and	and	CCONJ
ajst-26912	70	12	discussion	discussion	NOUN
ajst-26912	70	13	on	on	ADP
ajst-26912	70	14	related	related	ADJ
ajst-26912	70	15	risks	risk	NOUN
ajst-26912	70	16	in	in	ADP
ajst-26912	70	17	order	order	NOUN
ajst-26912	70	18	to	to	PART
ajst-26912	70	19	formulate	formulate	VERB
ajst-26912	70	20	more	more	ADV
ajst-26912	70	21	effective	effective	ADJ
ajst-26912	70	22	risk	risk	NOUN
ajst-26912	70	23	management	management	NOUN
ajst-26912	70	24	strategies	strategy	NOUN
ajst-26912	70	25	.	.	PUNCT
ajst-26912	71	1	4.4	4.4	NUM
ajst-26912	71	2	.	.	PUNCT
ajst-26912	72	1	risk	risk	NOUN
ajst-26912	72	2	management	management	NOUN
ajst-26912	72	3	strategy	strategy	NOUN
ajst-26912	72	4	to	to	PART
ajst-26912	72	5	mitigate	mitigate	VERB
ajst-26912	72	6	the	the	DET
ajst-26912	72	7	risks	risk	NOUN
ajst-26912	72	8	associated	associate	VERB
ajst-26912	72	9	with	with	ADP
ajst-26912	72	10	car	car	NOUN
ajst-26912	72	11	-	-	PUNCT
ajst-26912	72	12	t	t	NOUN
ajst-26912	72	13	cell	cell	NOUN
ajst-26912	72	14	therapy	therapy	NOUN
ajst-26912	72	15	and	and	CCONJ
ajst-26912	72	16	enhance	enhance	VERB
ajst-26912	72	17	patient	patient	ADJ
ajst-26912	72	18	safety	safety	NOUN
ajst-26912	73	1	,	,	PUNCT
ajst-26912	73	2	researchers	researcher	NOUN
ajst-26912	73	3	and	and	CCONJ
ajst-26912	73	4	clinicians	clinician	NOUN
ajst-26912	73	5	have	have	AUX
ajst-26912	73	6	implemented	implement	VERB
ajst-26912	73	7	various	various	ADJ
ajst-26912	73	8	risk	risk	NOUN
ajst-26912	73	9	management	management	NOUN
ajst-26912	73	10	strategies	strategy	NOUN
ajst-26912	73	11	.	.	PUNCT
ajst-26912	74	1	these	these	PRON
ajst-26912	74	2	include	include	VERB
ajst-26912	74	3	rigorous	rigorous	ADJ
ajst-26912	74	4	adherence	adherence	NOUN
ajst-26912	74	5	to	to	ADP
ajst-26912	74	6	quality	quality	NOUN
ajst-26912	74	7	standards	standard	NOUN
ajst-26912	74	8	and	and	CCONJ
ajst-26912	74	9	operational	operational	ADJ
ajst-26912	74	10	protocols	protocol	NOUN
ajst-26912	74	11	during	during	ADP
ajst-26912	74	12	car	car	NOUN
ajst-26912	74	13	-	-	PUNCT
ajst-26912	74	14	t	t	NOUN
ajst-26912	74	15	cell	cell	NOUN
ajst-26912	74	16	preparation	preparation	NOUN
ajst-26912	74	17	,	,	PUNCT
ajst-26912	74	18	conducting	conduct	VERB
ajst-26912	74	19	thorough	thorough	ADJ
ajst-26912	74	20	patient	patient	NOUN
ajst-26912	74	21	evaluations	evaluation	NOUN
ajst-26912	74	22	and	and	CCONJ
ajst-26912	74	23	screenings	screening	NOUN
ajst-26912	74	24	prior	prior	ADV
ajst-26912	74	25	to	to	ADP
ajst-26912	74	26	infusion	infusion	NOUN
ajst-26912	74	27	,	,	PUNCT
ajst-26912	74	28	and	and	CCONJ
ajst-26912	74	29	closely	closely	ADV
ajst-26912	74	30	monitoring	monitor	VERB
ajst-26912	74	31	patients	patient	NOUN
ajst-26912	74	32	'	'	PART
ajst-26912	74	33	vital	vital	ADJ
ajst-26912	74	34	signs	sign	NOUN
ajst-26912	74	35	and	and	CCONJ
ajst-26912	74	36	adverse	adverse	ADJ
ajst-26912	74	37	reactions	reaction	NOUN
ajst-26912	74	38	post	post	NOUN
ajst-26912	74	39	-	-	NOUN
ajst-26912	74	40	infusion	infusion	NOUN
ajst-26912	74	41	,	,	PUNCT
ajst-26912	74	42	with	with	ADP
ajst-26912	74	43	prompt	prompt	ADJ
ajst-26912	74	44	interventions	intervention	NOUN
ajst-26912	74	45	as	as	ADP
ajst-26912	74	46	necessary	necessary	ADJ
ajst-26912	74	47	.	.	PUNCT
ajst-26912	75	1	furthermore	furthermore	ADV
ajst-26912	75	2	,	,	PUNCT
ajst-26912	75	3	researchers	researcher	NOUN
ajst-26912	75	4	are	be	AUX
ajst-26912	75	5	continually	continually	ADV
ajst-26912	75	6	innovating	innovate	VERB
ajst-26912	75	7	in	in	ADP
ajst-26912	75	8	car	car	NOUN
ajst-26912	75	9	-	-	PUNCT
ajst-26912	75	10	t	t	NOUN
ajst-26912	75	11	cell	cell	NOUN
ajst-26912	75	12	design	design	NOUN
ajst-26912	75	13	and	and	CCONJ
ajst-26912	75	14	production	production	NOUN
ajst-26912	75	15	to	to	PART
ajst-26912	75	16	boost	boost	VERB
ajst-26912	75	17	efficacy	efficacy	NOUN
ajst-26912	75	18	and	and	CCONJ
ajst-26912	75	19	minimize	minimize	VERB
ajst-26912	75	20	adverse	adverse	ADJ
ajst-26912	75	21	effects	effect	NOUN
ajst-26912	75	22	.	.	PUNCT
ajst-26912	76	1	examples	example	NOUN
ajst-26912	76	2	include	include	VERB
ajst-26912	76	3	refining	refine	VERB
ajst-26912	76	4	car	car	NOUN
ajst-26912	76	5	molecule	molecule	NOUN
ajst-26912	76	6	structures	structure	NOUN
ajst-26912	76	7	to	to	PART
ajst-26912	76	8	decrease	decrease	VERB
ajst-26912	76	9	crs	crs	PROPN
ajst-26912	76	10	and	and	CCONJ
ajst-26912	76	11	icans	ican	VERB
ajst-26912	76	12	incidences	incidence	NOUN
ajst-26912	76	13	,	,	PUNCT
ajst-26912	76	14	and	and	CCONJ
ajst-26912	76	15	incorporating	incorporate	VERB
ajst-26912	76	16	novel	novel	ADJ
ajst-26912	76	17	costimulatory	costimulatory	NOUN
ajst-26912	76	18	molecules	molecule	NOUN
ajst-26912	76	19	to	to	PART
ajst-26912	76	20	augment	augment	VERB
ajst-26912	76	21	car	car	NOUN
ajst-26912	76	22	-	-	PUNCT
ajst-26912	76	23	t	t	NOUN
ajst-26912	76	24	cell	cell	NOUN
ajst-26912	76	25	persistence	persistence	NOUN
ajst-26912	76	26	and	and	CCONJ
ajst-26912	76	27	antitumor	antitumor	PROPN
ajst-26912	76	28	activity	activity	NOUN
ajst-26912	76	29	.	.	PUNCT
ajst-26912	77	1	5	5	X
ajst-26912	77	2	.	.	X
ajst-26912	77	3	conclusions	conclusion	NOUN
ajst-26912	77	4	car	car	PROPN
ajst-26912	77	5	-	-	PUNCT
ajst-26912	77	6	t	t	PROPN
ajst-26912	77	7	cell	cell	NOUN
ajst-26912	77	8	technology	technology	NOUN
ajst-26912	77	9	,	,	PUNCT
ajst-26912	77	10	a	a	DET
ajst-26912	77	11	pioneering	pioneer	VERB
ajst-26912	77	12	domain	domain	NOUN
ajst-26912	77	13	in	in	ADP
ajst-26912	77	14	tumor	tumor	NOUN
ajst-26912	77	15	immunotherapy	immunotherapy	NOUN
ajst-26912	77	16	,	,	PUNCT
ajst-26912	77	17	harbors	harbor	VERB
ajst-26912	77	18	substantial	substantial	ADJ
ajst-26912	77	19	clinical	clinical	ADJ
ajst-26912	77	20	application	application	NOUN
ajst-26912	77	21	promise	promise	NOUN
ajst-26912	77	22	.	.	PUNCT
ajst-26912	78	1	it	it	PRON
ajst-26912	78	2	has	have	AUX
ajst-26912	78	3	demonstrated	demonstrate	VERB
ajst-26912	78	4	impressive	impressive	ADJ
ajst-26912	78	5	outcomes	outcome	NOUN
ajst-26912	78	6	in	in	ADP
ajst-26912	78	7	the	the	DET
ajst-26912	78	8	management	management	NOUN
ajst-26912	78	9	of	of	ADP
ajst-26912	78	10	hematological	hematological	ADJ
ajst-26912	78	11	tumors	tumor	NOUN
ajst-26912	78	12	.	.	PUNCT
ajst-26912	79	1	nevertheless	nevertheless	ADV
ajst-26912	79	2	,	,	PUNCT
ajst-26912	79	3	its	its	PRON
ajst-26912	79	4	application	application	NOUN
ajst-26912	79	5	in	in	ADP
ajst-26912	79	6	treating	treat	VERB
ajst-26912	79	7	solid	solid	ADJ
ajst-26912	79	8	tumors	tumor	NOUN
ajst-26912	79	9	encounters	encounter	VERB
ajst-26912	79	10	numerous	numerous	ADJ
ajst-26912	79	11	hurdles	hurdle	NOUN
ajst-26912	79	12	,	,	PUNCT
ajst-26912	79	13	such	such	ADJ
ajst-26912	79	14	as	as	ADP
ajst-26912	79	15	intricate	intricate	ADJ
ajst-26912	79	16	antigen	antigen	NOUN
ajst-26912	79	17	expression	expression	NOUN
ajst-26912	79	18	patterns	pattern	NOUN
ajst-26912	79	19	and	and	CCONJ
ajst-26912	79	20	the	the	DET
ajst-26912	79	21	tumor	tumor	NOUN
ajst-26912	79	22	microenvironment	microenvironment	NOUN
ajst-26912	79	23	's	's	PART
ajst-26912	79	24	harsh	harsh	ADJ
ajst-26912	79	25	conditions	condition	NOUN
ajst-26912	79	26	.	.	PUNCT
ajst-26912	80	1	researchers	researcher	NOUN
ajst-26912	80	2	are	be	AUX
ajst-26912	80	3	diligently	diligently	ADV
ajst-26912	80	4	exploring	explore	VERB
ajst-26912	80	5	novel	novel	ADJ
ajst-26912	80	6	approaches	approach	NOUN
ajst-26912	80	7	to	to	PART
ajst-26912	80	8	enhance	enhance	VERB
ajst-26912	80	9	car	car	NOUN
ajst-26912	80	10	-	-	PUNCT
ajst-26912	80	11	t	t	NOUN
ajst-26912	80	12	cell	cell	NOUN
ajst-26912	80	13	therapy	therapy	NOUN
ajst-26912	80	14	's	's	PART
ajst-26912	80	15	efficacy	efficacy	NOUN
ajst-26912	80	16	against	against	ADP
ajst-26912	80	17	solid	solid	ADJ
ajst-26912	80	18	tumors	tumor	NOUN
ajst-26912	80	19	.	.	PUNCT
ajst-26912	81	1	accompanying	accompany	VERB
ajst-26912	81	2	car	car	NOUN
ajst-26912	81	3	-	-	PUNCT
ajst-26912	81	4	t	t	NOUN
ajst-26912	81	5	cell	cell	NOUN
ajst-26912	81	6	technology	technology	NOUN
ajst-26912	81	7	's	's	PART
ajst-26912	81	8	benefits	benefit	NOUN
ajst-26912	81	9	are	be	AUX
ajst-26912	81	10	a	a	DET
ajst-26912	81	11	spectrum	spectrum	NOUN
ajst-26912	81	12	of	of	ADP
ajst-26912	81	13	risks	risk	NOUN
ajst-26912	81	14	,	,	PUNCT
ajst-26912	81	15	spanning	span	VERB
ajst-26912	81	16	short	short	ADJ
ajst-26912	81	17	-	-	PUNCT
ajst-26912	81	18	term	term	NOUN
ajst-26912	81	19	adverse	adverse	ADJ
ajst-26912	81	20	reactions	reaction	NOUN
ajst-26912	81	21	like	like	ADP
ajst-26912	81	22	cytokine	cytokine	NOUN
ajst-26912	81	23	release	release	NOUN
ajst-26912	81	24	syndrome	syndrome	NOUN
ajst-26912	81	25	and	and	CCONJ
ajst-26912	81	26	immune	immune	ADJ
ajst-26912	81	27	effector	effector	NOUN
ajst-26912	81	28	cell	cell	NOUN
ajst-26912	81	29	-	-	PUNCT
ajst-26912	81	30	related	relate	VERB
ajst-26912	81	31	neurotoxicity	neurotoxicity	NOUN
ajst-26912	81	32	syndrome	syndrome	NOUN
ajst-26912	81	33	,	,	PUNCT
ajst-26912	81	34	to	to	ADP
ajst-26912	81	35	long	long	ADJ
ajst-26912	81	36	-	-	PUNCT
ajst-26912	81	37	term	term	NOUN
ajst-26912	81	38	safety	safety	NOUN
ajst-26912	81	39	concerns	concern	NOUN
ajst-26912	81	40	encompassing	encompass	VERB
ajst-26912	81	41	immunosuppression	immunosuppression	NOUN
ajst-26912	81	42	,	,	PUNCT
ajst-26912	81	43	immune	immune	ADJ
ajst-26912	81	44	dysregulation	dysregulation	NOUN
ajst-26912	81	45	,	,	PUNCT
ajst-26912	81	46	and	and	CCONJ
ajst-26912	81	47	secondary	secondary	ADJ
ajst-26912	81	48	malignancies	malignancy	NOUN
ajst-26912	81	49	.	.	PUNCT
ajst-26912	82	1	to	to	PART
ajst-26912	82	2	safeguard	safeguard	VERB
ajst-26912	82	3	patient	patient	ADJ
ajst-26912	82	4	safety	safety	NOUN
ajst-26912	82	5	,	,	PUNCT
ajst-26912	82	6	regulatory	regulatory	ADJ
ajst-26912	82	7	bodies	body	NOUN
ajst-26912	82	8	have	have	AUX
ajst-26912	82	9	implemented	implement	VERB
ajst-26912	82	10	stringent	stringent	ADJ
ajst-26912	82	11	oversight	oversight	NOUN
ajst-26912	82	12	measures	measure	NOUN
ajst-26912	82	13	and	and	CCONJ
ajst-26912	82	14	mandated	mandate	VERB
ajst-26912	82	15	the	the	DET
ajst-26912	82	16	development	development	NOUN
ajst-26912	82	17	of	of	ADP
ajst-26912	82	18	robust	robust	ADJ
ajst-26912	82	19	risk	risk	NOUN
ajst-26912	82	20	management	management	NOUN
ajst-26912	82	21	strategies	strategy	NOUN
ajst-26912	82	22	by	by	ADP
ajst-26912	82	23	researchers	researcher	NOUN
ajst-26912	82	24	and	and	CCONJ
ajst-26912	82	25	clinicians	clinician	NOUN
ajst-26912	82	26	.	.	PUNCT
ajst-26912	83	1	as	as	ADP
ajst-26912	83	2	research	research	NOUN
ajst-26912	83	3	progresses	progress	NOUN
ajst-26912	83	4	,	,	PUNCT
ajst-26912	83	5	car	car	NOUN
ajst-26912	83	6	-	-	PUNCT
ajst-26912	83	7	t	t	NOUN
ajst-26912	83	8	cell	cell	NOUN
ajst-26912	83	9	technology	technology	NOUN
ajst-26912	83	10	is	be	AUX
ajst-26912	83	11	poised	poise	VERB
ajst-26912	83	12	to	to	PART
ajst-26912	83	13	assume	assume	VERB
ajst-26912	83	14	a	a	DET
ajst-26912	83	15	more	more	ADV
ajst-26912	83	16	pivotal	pivotal	ADJ
ajst-26912	83	17	role	role	NOUN
ajst-26912	83	18	in	in	ADP
ajst-26912	83	19	tumor	tumor	NOUN
ajst-26912	83	20	treatment	treatment	NOUN
ajst-26912	83	21	,	,	PUNCT
ajst-26912	83	22	offering	offer	VERB
ajst-26912	83	23	hope	hope	NOUN
ajst-26912	83	24	to	to	ADP
ajst-26912	83	25	a	a	DET
ajst-26912	83	26	greater	great	ADJ
ajst-26912	83	27	number	number	NOUN
ajst-26912	83	28	of	of	ADP
ajst-26912	83	29	patients	patient	NOUN
ajst-26912	83	30	.	.	PUNCT
ajst-26912	84	1	continued	continue	VERB
ajst-26912	84	2	vigilance	vigilance	NOUN
ajst-26912	84	3	regarding	regard	VERB
ajst-26912	84	4	its	its	PRON
ajst-26912	84	5	safety	safety	NOUN
ajst-26912	84	6	and	and	CCONJ
ajst-26912	84	7	efficacy	efficacy	NOUN
ajst-26912	84	8	,	,	PUNCT
ajst-26912	84	9	along	along	ADP
ajst-26912	84	10	with	with	ADP
ajst-26912	84	11	ongoing	ongoing	ADJ
ajst-26912	84	12	refinement	refinement	NOUN
ajst-26912	84	13	of	of	ADP
ajst-26912	84	14	treatment	treatment	NOUN
ajst-26912	84	15	protocols	protocol	NOUN
ajst-26912	84	16	,	,	PUNCT
ajst-26912	84	17	remains	remain	VERB
ajst-26912	84	18	paramount	paramount	ADJ
ajst-26912	84	19	.	.	PUNCT
ajst-26912	85	1	references	reference	NOUN
ajst-26912	85	2	[	[	X
ajst-26912	85	3	1	1	X
ajst-26912	85	4	]	]	X
ajst-26912	85	5	liu	liu	PROPN
ajst-26912	85	6	s	s	PROPN
ajst-26912	85	7	,	,	PUNCT
ajst-26912	85	8	zhao	zhao	PROPN
ajst-26912	85	9	y	y	PROPN
ajst-26912	85	10	,	,	PUNCT
ajst-26912	85	11	gao	gao	PROPN
ajst-26912	85	12	y	y	PROPN
ajst-26912	85	13	,	,	PUNCT
ajst-26912	85	14	et	et	PROPN
ajst-26912	85	15	al	al	PROPN
ajst-26912	85	16	.	.	PUNCT
ajst-26912	85	17	targeting	target	VERB
ajst-26912	85	18	metabolism	metabolism	NOUN
ajst-26912	85	19	to	to	PART
ajst-26912	85	20	improve	improve	VERB
ajst-26912	85	21	car	car	NOUN
ajst-26912	85	22	-	-	PUNCT
ajst-26912	85	23	t	t	NOUN
ajst-26912	85	24	cells	cell	NOUN
ajst-26912	85	25	therapeutic	therapeutic	ADJ
ajst-26912	85	26	efficacy[j	efficacy[j	NOUN
ajst-26912	85	27	]	]	PUNCT
ajst-26912	85	28	.	.	PUNCT
ajst-26912	86	1	chinese	chinese	ADJ
ajst-26912	86	2	medical	medical	ADJ
ajst-26912	86	3	journal	journal	PROPN
ajst-26912	86	4	,	,	PUNCT
ajst-26912	86	5	2024	2024	NUM
ajst-26912	86	6	,	,	PUNCT
ajst-26912	86	7	137(8):909	137(8):909	NUM
ajst-26912	86	8	-	-	SYM
ajst-26912	86	9	920	920	NUM
ajst-26912	86	10	.	.	PUNCT
ajst-26912	87	1	[	[	X
ajst-26912	87	2	2	2	NUM
ajst-26912	87	3	]	]	X
ajst-26912	87	4	li	li	PROPN
ajst-26912	87	5	h	h	PROPN
ajst-26912	87	6	,	,	PUNCT
ajst-26912	87	7	yang	yang	PROPN
ajst-26912	87	8	x	x	PROPN
ajst-26912	87	9	,	,	PUNCT
ajst-26912	87	10	wang	wang	PROPN
ajst-26912	87	11	z	z	PROPN
ajst-26912	87	12	,	,	PUNCT
ajst-26912	87	13	et	et	PROPN
ajst-26912	87	14	al	al	PROPN
ajst-26912	87	15	.	.	PUNCT
ajst-26912	88	1	a	a	DET
ajst-26912	88	2	near	near	ADV
ajst-26912	88	3	-	-	PUNCT
ajst-26912	88	4	infrared	infrare	VERB
ajst-26912	88	5	-	-	PUNCT
ajst-26912	88	6	ii	ii	NOUN
ajst-26912	88	7	fluorescent	fluorescent	NOUN
ajst-26912	88	8	nanocatalyst	nanocatalyst	ADV
ajst-26912	88	9	for	for	ADP
ajst-26912	88	10	enhanced	enhanced	ADJ
ajst-26912	88	11	car	car	NOUN
ajst-26912	88	12	t	t	NOUN
ajst-26912	88	13	cell	cell	NOUN
ajst-26912	88	14	therapy	therapy	NOUN
ajst-26912	88	15	against	against	ADP
ajst-26912	88	16	solid	solid	ADJ
ajst-26912	88	17	tumor	tumor	NOUN
ajst-26912	88	18	by	by	ADP
ajst-26912	88	19	immune	immune	ADJ
ajst-26912	88	20	reprogramming[j	reprogramming[j	PROPN
ajst-26912	88	21	]	]	PUNCT
ajst-26912	88	22	.	.	PUNCT
ajst-26912	89	1	acs	acs	PROPN
ajst-26912	89	2	nano	nano	PROPN
ajst-26912	89	3	,	,	PUNCT
ajst-26912	89	4	2023	2023	NUM
ajst-26912	89	5	,	,	PUNCT
ajst-26912	89	6	17(12):11749	17(12):11749	NUM
ajst-26912	89	7	-	-	SYM
ajst-26912	89	8	11763	11763	NUM
ajst-26912	89	9	.	.	PUNCT
ajst-26912	90	1	[	[	X
ajst-26912	90	2	3	3	X
ajst-26912	90	3	]	]	X
ajst-26912	90	4	lu	lu	PROPN
ajst-26912	90	5	wenbin	wenbin	NOUN
ajst-26912	90	6	,	,	PUNCT
ajst-26912	90	7	gong	gong	PROPN
ajst-26912	90	8	xuechao	xuechao	PROPN
ajst-26912	90	9	,	,	PUNCT
ajst-26912	90	10	jin	jin	PROPN
ajst-26912	90	11	jianhua	jianhua	PROPN
ajst-26912	90	12	,	,	PUNCT
ajst-26912	90	13	et	et	PROPN
ajst-26912	90	14	al	al	PROPN
ajst-26912	90	15	.	.	PUNCT
ajst-26912	90	16	research	research	NOUN
ajst-26912	90	17	progress	progress	NOUN
ajst-26912	90	18	and	and	CCONJ
ajst-26912	90	19	optimization	optimization	NOUN
ajst-26912	90	20	strategy	strategy	NOUN
ajst-26912	90	21	of	of	ADP
ajst-26912	90	22	tcr	tcr	PROPN
ajst-26912	90	23	/	/	SYM
ajst-26912	90	24	car	car	NOUN
ajst-26912	90	25	modified	modify	VERB
ajst-26912	90	26	t	t	NOUN
ajst-26912	90	27	cells	cell	NOUN
ajst-26912	90	28	in	in	ADP
ajst-26912	90	29	tumor	tumor	NOUN
ajst-26912	90	30	immunotherapy	immunotherapy	NOUN
ajst-26912	91	1	[	[	X
ajst-26912	91	2	j	j	X
ajst-26912	91	3	]	]	X
ajst-26912	91	4	.	.	PUNCT
ajst-26912	92	1	journal	journal	PROPN
ajst-26912	92	2	of	of	ADP
ajst-26912	92	3	immunology	immunology	NOUN
ajst-26912	92	4	,	,	PUNCT
ajst-26912	92	5	2018	2018	NUM
ajst-26912	92	6	,	,	PUNCT
ajst-26912	92	7	34(02):163	34(02):163	NUM
ajst-26912	92	8	-	-	NOUN
ajst-26912	92	9	173	173	NUM
ajst-26912	92	10	.	.	PUNCT
ajst-26912	93	1	[	[	X
ajst-26912	93	2	4	4	NUM
ajst-26912	93	3	]	]	X
ajst-26912	93	4	dimitri	dimitri	PROPN
ajst-26912	93	5	a	a	X
ajst-26912	93	6	,	,	PUNCT
ajst-26912	93	7	herbst	herbst	PROPN
ajst-26912	93	8	f	f	PROPN
ajst-26912	93	9	,	,	PUNCT
ajst-26912	93	10	fraietta	fraietta	PROPN
ajst-26912	93	11	j	j	PROPN
ajst-26912	93	12	a.	a.	NOUN
ajst-26912	93	13	engineering	engineer	VERB
ajst-26912	93	14	the	the	DET
ajst-26912	93	15	nextgeneration	nextgeneration	NOUN
ajst-26912	93	16	of	of	ADP
ajst-26912	93	17	car	car	NOUN
ajst-26912	93	18	t	t	NOUN
ajst-26912	93	19	-	-	PUNCT
ajst-26912	93	20	cells	cell	NOUN
ajst-26912	93	21	with	with	ADP
ajst-26912	93	22	crispr	crispr	ADJ
ajst-26912	93	23	-	-	PUNCT
ajst-26912	93	24	cas9	cas9	NOUN
ajst-26912	93	25	gene	gene	NOUN
ajst-26912	93	26	editing[j	editing[j	PROPN
ajst-26912	93	27	]	]	PUNCT
ajst-26912	93	28	.	.	PUNCT
ajst-26912	94	1	molecular	molecular	ADJ
ajst-26912	94	2	cancer	cancer	NOUN
ajst-26912	94	3	,	,	PUNCT
ajst-26912	94	4	2022	2022	NUM
ajst-26912	94	5	,	,	PUNCT
ajst-26912	94	6	21(1):1	21(1):1	NUM
ajst-26912	94	7	-	-	SYM
ajst-26912	94	8	13	13	NUM
ajst-26912	94	9	.	.	PUNCT
ajst-26912	94	10	206	206	NUM
ajst-26912	95	1	[	[	X
ajst-26912	95	2	5	5	NUM
ajst-26912	95	3	]	]	X
ajst-26912	95	4	li	li	PROPN
ajst-26912	95	5	chunhui	chunhui	PROPN
ajst-26912	95	6	,	,	PUNCT
ajst-26912	95	7	li	li	PROPN
ajst-26912	95	8	chunrui	chunrui	PROPN
ajst-26912	95	9	.	.	PUNCT
ajst-26912	96	1	application	application	NOUN
ajst-26912	96	2	of	of	ADP
ajst-26912	96	3	car	car	NOUN
ajst-26912	96	4	-	-	PUNCT
ajst-26912	96	5	t	t	NOUN
ajst-26912	96	6	cell	cell	NOUN
ajst-26912	96	7	therapy	therapy	NOUN
ajst-26912	96	8	in	in	ADP
ajst-26912	96	9	autoimmune	autoimmune	ADJ
ajst-26912	96	10	diseases	disease	NOUN
ajst-26912	97	1	[	[	X
ajst-26912	97	2	j	j	X
ajst-26912	97	3	]	]	X
ajst-26912	97	4	.	.	PUNCT
ajst-26912	98	1	journal	journal	PROPN
ajst-26912	98	2	of	of	ADP
ajst-26912	98	3	internal	internal	ADJ
ajst-26912	98	4	medicine	medicine	NOUN
ajst-26912	98	5	,	,	PUNCT
ajst-26912	98	6	2023	2023	NUM
ajst-26912	98	7	,	,	PUNCT
ajst-26912	98	8	29(5):363	29(5):363	PROPN
ajst-26912	98	9	-	-	SYM
ajst-26912	98	10	369	369	NUM
ajst-26912	98	11	.	.	PUNCT
ajst-26912	99	1	[	[	X
ajst-26912	99	2	6	6	NUM
ajst-26912	99	3	]	]	X
ajst-26912	99	4	zhang	zhang	PROPN
ajst-26912	99	5	guizhen	guizhen	PROPN
ajst-26912	99	6	,	,	PUNCT
ajst-26912	99	7	yu	yu	PROPN
ajst-26912	99	8	zujiang	zujiang	PROPN
ajst-26912	99	9	,	,	PUNCT
ajst-26912	99	10	han	han	PROPN
ajst-26912	99	11	shuangyin	shuangyin	PROPN
ajst-26912	99	12	.	.	PUNCT
ajst-26912	100	1	research	research	NOUN
ajst-26912	100	2	progress	progress	NOUN
ajst-26912	100	3	of	of	ADP
ajst-26912	100	4	b7	b7	PROPN
ajst-26912	100	5	-	-	PUNCT
ajst-26912	100	6	h3	h3	NOUN
ajst-26912	100	7	targeting	target	VERB
ajst-26912	100	8	car	car	NOUN
ajst-26912	100	9	-	-	PUNCT
ajst-26912	100	10	t	t	NOUN
ajst-26912	100	11	cells	cell	NOUN
ajst-26912	100	12	in	in	ADP
ajst-26912	100	13	solid	solid	ADJ
ajst-26912	100	14	tumor	tumor	NOUN
ajst-26912	100	15	immunotherapy	immunotherapy	NOUN
ajst-26912	101	1	[	[	X
ajst-26912	101	2	j	j	X
ajst-26912	101	3	]	]	X
ajst-26912	101	4	.	.	PUNCT
ajst-26912	102	1	china	china	PROPN
ajst-26912	102	2	journal	journal	PROPN
ajst-26912	102	3	of	of	ADP
ajst-26912	102	4	immunology	immunology	NOUN
ajst-26912	102	5	,	,	PUNCT
ajst-26912	102	6	2022	2022	NUM
ajst-26912	102	7	,	,	PUNCT
ajst-26912	102	8	38(21):2650	38(21):2650	NUM
ajst-26912	102	9	-	-	SYM
ajst-26912	102	10	2655	2655	NUM
ajst-26912	102	11	.	.	PUNCT
ajst-26912	103	1	[	[	X
ajst-26912	103	2	7	7	X
ajst-26912	103	3	]	]	X
ajst-26912	103	4	zhang	zhang	PROPN
ajst-26912	103	5	z	z	PROPN
ajst-26912	103	6	,	,	PUNCT
ajst-26912	103	7	yang	yang	PROPN
ajst-26912	103	8	n	n	PROPN
ajst-26912	103	9	,	,	PUNCT
ajst-26912	103	10	xu	xu	PROPN
ajst-26912	103	11	l	l	PROPN
ajst-26912	103	12	,	,	PUNCT
ajst-26912	103	13	et	et	PROPN
ajst-26912	103	14	al	al	PROPN
ajst-26912	103	15	.	.	PUNCT
ajst-26912	104	1	systemic	systemic	ADJ
ajst-26912	104	2	delivery	delivery	NOUN
ajst-26912	104	3	of	of	ADP
ajst-26912	104	4	oncolytic	oncolytic	ADJ
ajst-26912	104	5	herpes	herpe	NOUN
ajst-26912	104	6	virus	virus	NOUN
ajst-26912	104	7	using	use	VERB
ajst-26912	104	8	car	car	NOUN
ajst-26912	104	9	-	-	PUNCT
ajst-26912	104	10	t	t	NOUN
ajst-26912	104	11	cells	cell	NOUN
ajst-26912	104	12	enhances	enhance	VERB
ajst-26912	104	13	targeting	target	VERB
ajst-26912	104	14	of	of	ADP
ajst-26912	104	15	antitumor	antitumor	PROPN
ajst-26912	104	16	immuno	immuno	PROPN
ajst-26912	104	17	-	-	PUNCT
ajst-26912	104	18	virotherapy[j	virotherapy[j	NOUN
ajst-26912	104	19	]	]	PUNCT
ajst-26912	104	20	.	.	PUNCT
ajst-26912	105	1	cancer	cancer	NOUN
ajst-26912	105	2	immunology	immunology	NOUN
ajst-26912	105	3	,	,	PUNCT
ajst-26912	105	4	immunotherapy	immunotherapy	NOUN
ajst-26912	105	5	,	,	PUNCT
ajst-26912	105	6	2024	2024	NUM
ajst-26912	105	7	,	,	PUNCT
ajst-26912	105	8	73(9):1	73(9):1	PROPN
ajst-26912	105	9	-	-	SYM
ajst-26912	105	10	14	14	NUM
ajst-26912	105	11	.	.	PUNCT
ajst-26912	106	1	[	[	X
ajst-26912	106	2	8	8	NUM
ajst-26912	106	3	]	]	SYM
ajst-26912	106	4	vagnozzi	vagnozzi	NOUN
ajst-26912	106	5	r	r	PROPN
ajst-26912	106	6	j	j	PROPN
ajst-26912	106	7	,	,	PUNCT
ajst-26912	106	8	mckinsey	mckinsey	PROPN
ajst-26912	106	9	t	t	PROPN
ajst-26912	106	10	a.	a.	NOUN
ajst-26912	106	11	t	t	PROPN
ajst-26912	106	12	cell	cell	NOUN
ajst-26912	106	13	immunotherapy	immunotherapy	NOUN
ajst-26912	106	14	for	for	ADP
ajst-26912	106	15	cardiac	cardiac	ADJ
ajst-26912	106	16	fibrosis	fibrosis	NOUN
ajst-26912	106	17	:	:	PUNCT
ajst-26912	106	18	mrna	mrna	PROPN
ajst-26912	106	19	starts	start	VERB
ajst-26912	106	20	the	the	DET
ajst-26912	106	21	car[j	car[j	NOUN
ajst-26912	106	22	]	]	PUNCT
ajst-26912	106	23	.	.	PUNCT
ajst-26912	107	1	cell	cell	NOUN
ajst-26912	107	2	stem	stem	NOUN
ajst-26912	107	3	cell	cell	NOUN
ajst-26912	107	4	,	,	PUNCT
ajst-26912	107	5	2022	2022	NUM
ajst-26912	107	6	,	,	PUNCT
ajst-26912	107	7	29(3):352	29(3):352	NUM
ajst-26912	107	8	-	-	SYM
ajst-26912	107	9	354	354	NUM
ajst-26912	107	10	.	.	PUNCT
ajst-26912	108	1	[	[	X
ajst-26912	108	2	9	9	NUM
ajst-26912	108	3	]	]	SYM
ajst-26912	108	4	grosser	gross	ADJ
ajst-26912	108	5	r	r	NOUN
ajst-26912	108	6	,	,	PUNCT
ajst-26912	108	7	cherkassky	cherkassky	NOUN
ajst-26912	108	8	l	l	NOUN
ajst-26912	108	9	,	,	PUNCT
ajst-26912	108	10	chintala	chintala	PROPN
ajst-26912	108	11	n	n	CCONJ
ajst-26912	108	12	,	,	PUNCT
ajst-26912	108	13	et	et	PROPN
ajst-26912	108	14	al	al	PROPN
ajst-26912	108	15	.	.	PROPN
ajst-26912	108	16	combination	combination	NOUN
ajst-26912	108	17	immunotherapy	immunotherapy	NOUN
ajst-26912	108	18	with	with	ADP
ajst-26912	108	19	car	car	NOUN
ajst-26912	108	20	t	t	NOUN
ajst-26912	108	21	cells	cell	NOUN
ajst-26912	108	22	and	and	CCONJ
ajst-26912	108	23	checkpoint	checkpoint	NOUN
ajst-26912	108	24	blockade	blockade	NOUN
ajst-26912	108	25	for	for	ADP
ajst-26912	108	26	the	the	DET
ajst-26912	108	27	treatment	treatment	NOUN
ajst-26912	108	28	of	of	ADP
ajst-26912	108	29	solid	solid	ADJ
ajst-26912	108	30	tumors[j	tumors[j	NOUN
ajst-26912	108	31	]	]	PUNCT
ajst-26912	108	32	.	.	PUNCT
ajst-26912	109	1	cancer	cancer	NOUN
ajst-26912	109	2	cell	cell	NOUN
ajst-26912	109	3	,	,	PUNCT
ajst-26912	109	4	2019	2019	NUM
ajst-26912	109	5	,	,	PUNCT
ajst-26912	109	6	36(5):471	36(5):471	NUM
ajst-26912	109	7	-	-	SYM
ajst-26912	109	8	482	482	NUM
ajst-26912	109	9	.	.	PUNCT